Advertisement

P

  • Franz von Bruchhausen
  • Siegfried Ebel
  • Eberhard Hackenthal
  • Ulrike Holzgrabe
  • Margitta Albinus
  • Gudrun Amschler
  • Erwin von Angerer
  • C. Arras-Reiter
  • Andrea Bauer
  • Pia Bauer
  • Winfried Beil
  • Thorsten Beyrich
  • Katja Binder
  • Roswitha Böhme
  • Hans-Hubertus Borchert
  • Franz Bossle
  • Franz Bracher
  • Helmut Bräunlich
  • Ellen Bretschneider
  • Regina Brigelius-Flohé
  • Kerstin Brinkmann
  • Axel Büge
  • Wolfram Christ
  • Monika Cimbollek
  • Rolf Daniels
  • Gerd Dannhardt
  • Hans-Jürgen Duchstein
  • Kurt Eger
  • Petra Eichhorn
  • Michael Engler
  • Thomas Erker
  • Peter Felfe
  • Alfred Fenyves
  • Reinhard Fescharek
  • Carmen Frackenpohl
  • August Wilhelm Frahm
  • Margarete Frahm
  • Volker Franke
  • Ulrich Franken
  • Detlef Geffken
  • Uli Geis
  • Erika Glusa
  • Berthold Göber
  • Peter Ndive Gobina
  • Werner Golder
  • Margarete Goppelt-Strübe
  • Katharina Götte
  • Erkme Gottstein
  • Michael Grosam
  • Markus von Gruchalla
  • Michael Gütschow
  • Annette Häfner
  • Boris Haluszczynski
  • Achim Harder
  • Sabine Hartmann
  • Susanne Hartmann
  • Dieter Heber
  • Gerhard Heinemeyer
  • Eberhard Heller
  • Dietrich von Herrath
  • J. Hilfenhaus
  • Ute Hoffmann-Schollmayer
  • Bernhard Hofmann
  • Christian Holpert
  • Ute Hübner-Steiner
  • Elisabeth Inkmann
  • Jens Jürgens
  • Brigitte Kaiser
  • Dieter-Abbo Kalbhen
  • Hans Kemmler
  • Werner Kiefer
  • Christoph Klett
  • Stephanie Klett
  • Martin Klingmüller
  • Hans-Peter Klöcking
  • Gerd Kobal
  • Axel Kramer
  • Mareta Kreher
  • M. Krüger
  • Markus Kuhn
  • Marion Sylvia Lehner
  • Detlef Leopoldt
  • Georg Liedtke
  • Detlef Manns
  • Wolfgang Matthiessen
  • Andreas Maurer
  • Wolfgang Meindl
  • Klaus Menges
  • Paul Messinger
  • Frank Peter Meyer
  • Wolfgang Meyerhof
  • Manfred Moos
  • Rudolf Morgenstern
  • Klaus Müller
  • Walter E. Müller
  • Corina Nachtsheim
  • Tilo Netzer
  • Michael Neugebauer
  • Werner Neupert
  • Peter Nickel
  • Peter Nuhn
  • Bernd Nürnberg
  • H. Oelschläger
  • Joachim Oertel
  • Michael Oettel
  • Hartmut Oßwald
  • Robert Ott
  • Tilmann Ott
  • Thomas Otzen
  • Peter Pachaly
  • Helmut Pelzer
  • Karl-Uwe Petersen
  • Rainer Pick
  • Martina Pickert
  • Andreas Pies
  • Eberhard Reimann
  • Joachim Richter
  • Kai Riecke
  • Suzanne Ritter
  • Hans Rommelspacher
  • Ulrich Rose
  • Gernot Roth
  • Gerhard Rücker
  • Judith Schäfer
  • Joachim G. Schantl
  • Helmut Schlager
  • Hildegard Schleinitz
  • Max Schmauß
  • Helmut Schmidhammer
  • Gerhard Schmidt
  • Timo Schmidt
  • B. Schneeweiß
  • Johannes Schräder
  • Thomas Schulz
  • Gert Schulze
  • Peter Schwanz
  • Johannes Schweiger
  • Gisela Skopp
  • Gisela Skorka
  • Kai Smolinka
  • Ulrich Speck
  • Ralf Stahlmann
  • Herbert Stein
  • Karlheinz Stiefvater
  • Karl-Heinz Surborg
  • Ulf Sürig
  • Hubert Szelényi
  • Istvan Szelenyi
  • Alfred Täufel
  • Ruth Thieroff-Ekerdt
  • Reinhard Troschütz
  • Michael Verborg
  • Eugen J. Verspohl
  • Sabine Vogel
  • Franz-Josef Volk
  • Thomas Vorwerk
  • Jürgen Wallmann
  • Martin Wenzel
  • Marion Weyandt-Spangenberg
  • Sandra Wich
  • Reinhold Wintersteiger
  • Frauke Woltmann
  • Beate Wüst
  • G. Zilow
  • A. Kluge
Chapter
  • 128 Downloads

Literatur

  1. 1.
    Bristol-Myers Squibb (1995) Drugs Fut 20:91–111Google Scholar
  2. 2.
    Helwig H, Otto HH (1994) Arzneimittel 2:67–69Google Scholar
  3. 3.
    Wani MC, Taylor HL, Wall ME (1971) J Am Chem Soc 93:2325–2327PubMedCrossRefGoogle Scholar
  4. 4.
    Nicolaou KC, Guy RK, Potier P (1996) Spektrum der Wissenschaft 8:76–80Google Scholar
  5. 5.
    Nicolaou KC, Yang Z, Liu JJ, Ueno H et al. (1994) Nature 367:630–634PubMedCrossRefGoogle Scholar
  6. 6.
    Blechert S, Guénard D (1990) Chem Pharm 39:195–238CrossRefGoogle Scholar
  7. 7.
    Swindell CS (1991) Org Prep Proced Int 23:465–543CrossRefGoogle Scholar
  8. 8.
    Falzone CJ, Benesi AJ, Lecomte JT (1992) THL 33:1169–1172Google Scholar
  9. 9.
    Stierte A, Strobel G, Stierte D (1993) Science 260:214–216CrossRefGoogle Scholar
  10. 1.
    Rao CV, Riverson A, Kelloff GJ, Reddy BS (1995) Anticancer Res 15:1199PubMedGoogle Scholar
  11. 2.
    Shimpo K, Takahashi H, Tsuda H, Hibino T, Kawai K, Kimura C, Nagatsu T, Fujita K (1996) Cancer Detect Prev 20:137PubMedGoogle Scholar
  12. 3.
    Wargovich MJ, Harris C, Chen CD, Palmer C, Steele VE, Kelloff GJ (1992) J Cell Biochem Suppl 16G:51PubMedCrossRefGoogle Scholar
  13. 4.
    Smart RC, Grawford CL (1991) Am J Clin Nutr Suppl 54:1266SGoogle Scholar
  14. 5.
    Tyrsina EG, Rossikhina OG, Abilev SK, Tyrsin YuA (1994) Mutat Res 321:81PubMedCrossRefGoogle Scholar
  15. 6.
    Naidu AK, Wiranowska M, Kori SH, Roetzheim KC, Kulkarni AP (1993) J Neurooncol 16:1PubMedCrossRefGoogle Scholar
  16. 1.
    Tatemoto K (Leland Stanford University) (1988) PCT Int. Appl. WO 8803536, US Appl. 927836; zit. nach CA 110:115346zGoogle Scholar
  17. 2.
    Schmidt WE, Creutzfeld W (1991) Acta Oncol 30:441–449PubMedCrossRefGoogle Scholar
  18. 3.
    Kitayama N, Tateishi K, Kono A Funakoshi A, Matsuoka Y (1994) Regul Pept 52:195–203; zit. nach CA 121:125846dPubMedCrossRefGoogle Scholar
  19. 4.
    Borglum-Jensen TD, Holst JJ, Fahrenkrug J (1991) Scand J Clin Lab Invest 51:681–691PubMedCrossRefGoogle Scholar
  20. 1.
    Flood JF, Morley JE, Tatemoto K (1988) Effects of systemic pancreastatin on memory retention. Peptides 9:1077–1080PubMedCrossRefGoogle Scholar
  21. 2.
    Funakoshi A, Tateishi K, Shinozaki H et al. (1990) Elevated plasma levels of pancreastatin (PST) in patients with non-insulin-dependent diabetes mellitus (NIDDM). Regul Pept 30:159–164PubMedCrossRefGoogle Scholar
  22. 3.
    Gorr SU, Pence SS (1995) Pancreastatin stimulates secretion from neonatal rat atrial cells. J Mol Cell Cardiol 27:767–771PubMedCrossRefGoogle Scholar
  23. 4.
    Haberstock-Debic H, Banfic H, Stevens WJ et al. (1997) Stimulation of T-cell proliferation by pancreastatin and its C-terminal fragment (33–49). Neuroimmunomodulation 4:244–249PubMedGoogle Scholar
  24. 5.
    Jensen TD, Holst JJ, Fahrenkrug J (1994) Secretion of pancreastatin from the porcine digestive tract. Scand J Gastroenterol 29:376–384PubMedCrossRefGoogle Scholar
  25. 6.
    Jin L, Scheithauer BW, Young WF et al. (1996) Pancreastatin secretion by pituitary adenomas and regulation of chromogranin B mRNA expression. Am J Pathol 148:2057–2066PubMedGoogle Scholar
  26. 7.
    Lindskog S, Skoglund G, Ahren B (1992) Pancreastatin inhibits insulin secretion from isolated rat islets: studies on its mechanism of action. Diabetes Res 19:119–123PubMedGoogle Scholar
  27. 8.
    Lindstrom E, Bjorkqvist M, Boketoft A et al. (1997) Neurohomonal regulation of histamine and pancreastatin secretion from isolated rat somach ECL cells. Regul Pept 71:73–86PubMedCrossRefGoogle Scholar
  28. 9.
    Ma HT, Kato M, Tatemoto K (1996) Effects of pancreastatin and somatostatin on secretagogues-induced rise in intracellular free calcium in single rat pancreatic islet cells. Regul Pept 61:143–148PubMedCrossRefGoogle Scholar
  29. 10.
    Kitayama N, Tateishi K, Funakoshi A et al. (1994) Production and secretion of chromogranin A and pancreastatin by the human pancreatic carcinoma cell line QGP-1N on stimulation with carbachol. Regul Pept 52:195–203PubMedCrossRefGoogle Scholar
  30. 11.
    O’Connor AM, Johnston CF, Buchanan KD et al. (1995) Circulating gastrointestinal hormone changes in marathon running. Int J Sports Med 16:283–287PubMedCrossRefGoogle Scholar
  31. 12.
    Sanchez-Margalet V, Valle M, Lobon JA et al. (1995) Plasma pancreastatin-like immunoreactivity correlates with plasma norepinephrine levels in essential hypertension. Neuropeptides 29:97–101PubMedCrossRefGoogle Scholar
  32. 13.
    Sanchez-Margalet V, Lobon JA, Gonzalez A et al. (1998) Increased plasma pancreastatin-like levels in gestational diabetes: correlation with catecholamine levels. Diabetes Care 21:1951–1954PubMedCrossRefGoogle Scholar
  33. 14.
    Sanchez-Margalet V, Goberna R (1994) Pancreastatin inhibits insulin-stimulated glycogen synthesis but not glycolysis in rat hepatocytes. Regul Pept 51:215–220PubMedCrossRefGoogle Scholar
  34. 15.
    Sanchez-Margalet V, Santos-Alvarez J (1997) Solubilization and molecular characterization of active pancreastatin receptors from rat liver membranes. Endocrinol 138:1712–1718CrossRefGoogle Scholar
  35. 16.
    Sanchez-Margalet V, Lucas M, Goberna R (1996) Pancreastatin: further evidence for its consideration as a regulatory peptide. J Mol Endocrinol 16:1–8PubMedCrossRefGoogle Scholar
  36. 17.
    Sanchez-Margalet V, Gonzalez-Yanes C (1998) Pancreastatin inhibits insulin action in rat adipocytes. Am J Physiol 275:E 1055–1060Google Scholar
  37. 18.
    Santos-Alvarez J, Sanchez-Margalet V (1998) Pancreastatin activates beta 3 isoform of phospholipase C via G (alpha) 11 protein stimulation in rat liver membranes. Mol Cell Endocrinol 143:101–106PubMedCrossRefGoogle Scholar
  38. 19.
    Sekiya K, Nakao R, Takayanagi R et al. (1994) Unique change of pancreastatin-like immunoreactivity in cerebrospinal fluid by aging. Neurosci Lett 170:179–182PubMedCrossRefGoogle Scholar
  39. 20.
    Siegel EG, Gallwitz B, Folsch UR (1998) Effect of human pancreastatin peptide (hP-16) on oral glucose tolerance in man. Exp Endocrinol Diabetes 106:178–182CrossRefGoogle Scholar
  40. 21.
    Syversen U, Opsjon SL, Stridsberg M et al. (1996) Chromogranin A and pancreastatin-like immunoreactivity in normal pregnancies. J Clin Endocrinol Metab 81:4470–4475PubMedCrossRefGoogle Scholar
  41. 22.
    Tateishi K, Miyasaka K, Shinozaki H et al. (1990) Pancreastatin-like immunoreactivity in urine. J Clin Endocrinol Metab 71:842–845PubMedCrossRefGoogle Scholar
  42. 23.
    Tateishi K, Funakoshi A, Hashimoto C et al. (1992) Degradation of human pancreastatin-52 by human kidney extract. Life Sci 50:607–613PubMedCrossRefGoogle Scholar
  43. 24.
    Zhang JX, Fasciotto BH, Darling DS et al. (1994) Pancreastatin, a chromogranin A-derived peptide, inhibits transcription of the parathyroid hormone and chromogranin A genes and decreases the stability of the respective messenger ribonucleic acids in parathyroid cells in culture. Endocrinol 134:1310–1316CrossRefGoogle Scholar
  44. 1.
    Kohl B, Sturm E, Senn-Bilfinger J, Simon WA, Krüger U, Schäfer H, Rainer G, Figala V, Klemm K (1992) J Med Chem 35:1049–1057PubMedCrossRefGoogle Scholar
  45. 2.
    Tanaka M, Yamazaki H, Hakusui H (1995) Chirality 7:612–615CrossRefGoogle Scholar
  46. 3.
    Huber R, Müller W, Banks MC, Rogers SJ, Norwood PC, Doyle E (1990) J Chromatogr 529:389–401PubMedCrossRefGoogle Scholar
  47. 1.
    Shin JM, Besancon ML, Simon A, Sachs G (1993) Biochem Biophys Asta 1148:223–233CrossRefGoogle Scholar
  48. 2.
    Beil W, Staar U, Sewing K-Fr (1992) Eur J Pharmacol 218:265–271PubMedCrossRefGoogle Scholar
  49. 3.
    Kohl B, Sturm E, Senn-Bilfirger J, Simon WA, Krüger U, Schaefer H, Rainer G, Figala V, Klemm K (1992) J Med Chem 35:1049–1057PubMedCrossRefGoogle Scholar
  50. 4.
    Simon WA, Keeling DJ, Laing SM, Fallowfield C, Tylor AG (1990) Biochem Pharmacol 39:1799–1806PubMedCrossRefGoogle Scholar
  51. 5.
    Kromer W, Postius S, Riedel R, Simon WA, Hanauer G, Brand U, Gönne S, Parson ME (1990) J Pharmacol Exp Ther 254:129–135PubMedGoogle Scholar
  52. 6.
    Hannan A, Weil J, Broom C, Walt RP (1992) Aliment Pharmacol Ther 6:373–380PubMedCrossRefGoogle Scholar
  53. 7.
    Suerbaum S, Leying H, Klemm K, Opferkuch W (1991) J Clin Microbiol Infect Dis 10:93–94CrossRefGoogle Scholar
  54. 8.
    Pue MA, Laroche J, Meinecke I, de Mey C (1993) Eur J Clin Phramacol 44:575–578CrossRefGoogle Scholar
  55. 9.
    Tucker GT (1994) Aliment Pharmacol Ther 8(Suppl 1):33–38PubMedGoogle Scholar
  56. 10.
    Fitton A, Wiseman L (1996) Drugs 51:460–482PubMedCrossRefGoogle Scholar
  57. 11.
    Byk Gulden (1994) Fachinformation PantozolGoogle Scholar
  58. 1.
    Palmer JL (1986) J Chromatogr 382:338–342PubMedCrossRefGoogle Scholar
  59. 2.
    Rohmann C, Friedrich K (1940) Arch Pharm 278:456–464CrossRefGoogle Scholar
  60. 3.
    De Freo RJ, Strickler PD (1963) J Org Chem 28:2915–2917CrossRefGoogle Scholar
  61. 4.
    Theus PM, Weuffen W, Herrmann H (1967) Pharmazie 22:584–590PubMedGoogle Scholar
  62. 5.
    Miner DJ, Rice JR, Riggin RM, Kissinger PT (1981) Anal Chem 53:2258–2263CrossRefGoogle Scholar
  63. 1.
    Lachard J, Jars G, Ged S (1969) Étude clinique des proprietes antalgiques du parapropamol en stomatologie. Revue d’Ondonto-Stomatologie du midi de la France 27:274–280Google Scholar
  64. 2.
    Podesta M, Aubert D (1970) Contribution a l’étude pharmacologique du parapropamol. Bollettino Chimico Farmceutico, 109:528–544Google Scholar
  65. 1.
    Hirsh J, Levin MN (1992) Low molecular weight heparin. Blood 79:1–17PubMedGoogle Scholar
  66. 2.
    Frampton JE, Faulds D (1994) Parnaparin. A review of its pharmacology, and clinical application in the prevention and treatment of thromboembolic and other vascular disorders. Drugs 47:652–676PubMedCrossRefGoogle Scholar
  67. 3.
    Dettori AG, Tagliaferri A, Dall’aglio E, Pini M (1988) Clinical pharmacology of a new low molecular weight heparin (Alfa LMWH-Fluxum). Int Angiol 7(Suppl. 3):7–18PubMedGoogle Scholar
  68. 4.
    Palmieri G, Ambrosi G, Agrati AM, Ferraro G, Marcozzi S (1988) A new low melocular weight heparin in the treatment of peripheral arterial disease. Int Angiol 7(Suppl 3):41–47PubMedGoogle Scholar
  69. 5.
    Melandri G, Semprini F, Cervi V, Candiotti N, Branzi A, Palazzini E, Magnani B (1993) Comparison of efficacy of low molecular weight heparin (parnaparin) with that of unfractionated heparin in the presence of activated platelets in healthy subjects. Am J Cardiol 72:450–454PubMedCrossRefGoogle Scholar
  70. 6.
    Melandri G, Semprini F, Cervi V, Candiotti N, Pallazzini E, Branzi A, Magnani B (1993) Benefit of adding low molecular weight heparin to the conventional treatment of stable angina pectoris. Circulation 88:2517–2523PubMedCrossRefGoogle Scholar
  71. 7.
    Barbanti M, Mastacchi R (1987) The effect of heparin and OP/LMWH on the release of plasminogen activator in perfused rat hind legs. Thromb Haemost 58:554Google Scholar
  72. 8.
    Abildgaard U, Lindahl AK, Sandset PM (1991) Heparin requires both antithrombin and extrinsic pathway inhibitor for its anticoagulant effect in human blood. Haemostasis 21:254–257PubMedGoogle Scholar
  73. 9.
    Palmieri G, Ambrosi G, Ferrero G, Palazzini E, Cossarizza A, et al. (1988) Kinetic control of low molecular weight heparin antithrombotic activity. Eur Rev Med Parmacol Sci 10:187–192Google Scholar
  74. 10.
    Becchi G, Bonomo GM, Scattarella M, Catania G, Salanitri T, Palazzini E (1993) Dose-effect relationship in the prevention of post-surgical thromboembolism by a lowmolecular-weight heparin. Acta Ther 19:163–177Google Scholar
  75. 11.
    Speziale F, Verardi S, Taurino M, Nicolini G, Rizzo L, Fiorani P, Palazzini E (1988) Low molecular weight heparin prevention of post-operative deep vein thrombosis in vascular surgery. Pharmatherapeutica 5:261–268PubMedGoogle Scholar
  76. 12.
    Gruttadauria G, Palazzini E (1993) Open study of the medical treatment of postphlebitic syndromes with a new low molecular weight heparin: parnaparin. Prog Rep 5:13–20Google Scholar
  77. 13.
    Mannarino E, Pasqualini L, Innocente S, Orlandi U, Scricciolo V, Lombardini R, Ciuffetti G (1991) Efficacy of low-molecular-weight heparin in the management of intermittent claudication. Angiology 42:1–7PubMedCrossRefGoogle Scholar
  78. 1.
    Drugs Fut (1986) 11(2): 112-115Google Scholar
  79. 1.
    Dechant KL, Clissold SP (1991) Paroxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Drugs 41:225–253PubMedCrossRefGoogle Scholar
  80. 2.
    Cohn JB, Wilcox CA (1985) A comparison of fluoxetine, imipramine, and placebo, in patients with major depressive disorder. J Clin Psychiat 46(Sec 2):26–31Google Scholar
  81. 3.
    Stark P, Hardison CD (1985) A review of multicenter controlled studies of fluoxetine vs imipramine and placebo in outpatients with major depressive disorder. J Clin Psychiat 46(Sec 2):53–58Google Scholar
  82. 4.
    Bourin M (1990) A double-blind comparison of paroxetine and clomipramine in depressed outpatients. Abstract from Proceedings of 17th CINP Congress, Kyoto, 10–14 Sep.Google Scholar
  83. 5.
    Guillibert E, Pelicier Y, Archambault JC, Chabannes JP, Clerc G, Desvilles M, Guibert M, Pagot R, Poisat JL, Thobie Y (1989) A double-blind, multicenter study of paroxetine versus clomipramine in depressed elderly patients. Acta Psychiat. Scand 80:132–134Google Scholar
  84. 6.
    Couinard G (1985) A double-blind controlled trial of fluoxetine and amitriptyline in the treatment of outpatients with major depressive disorder. J Clin Psychiat 46(Sec 2):32–37Google Scholar
  85. 7.
    Feighner JP (1985) A comparative trial of fluoxetine and amitriptyline in patients with major depression. J Clin Psychiat 46:369–372Google Scholar
  86. 8.
    Dahl LE, Dencker SJ, Lundin L (1981) A double-blind study of dothiepin hydrochloride (Prothiaden) and amitriptyline in outpatients with masked depression. J Int Med Res 9:103–107PubMedGoogle Scholar
  87. 9.
    Shillingford JS, Hindmarch I, Clarke A, Vince MJ (1990) A double-blind comparison of paroxetine and dothiepin on efficacy and tolerability in depressed community patients. Abstract from Proceedings of 17th CINP Congress, Kyoto: 10–14 Sep.Google Scholar
  88. 10.
    Dorman T (1990) A double-blind comparison of paroxetine and mianserin on sleep in elderly depressed hospital patients. Abstract from Proceedings of 17th CINP Congress, Kyoto:10-14 Sep.Google Scholar
  89. 11.
    Mertens C, Pintens H (1988) Paroxetine in the treatment of depression: a double-blind multicenter study versus mianserin. Acta Psychiat Scand 77:683–688PubMedCrossRefGoogle Scholar
  90. 12.
    Thomas DR, Nelson DR, Johnson AM (1987) Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor. Psychopharmacology 93:193–200PubMedCrossRefGoogle Scholar
  91. 13.
    Buus Lassen J (1978) Potent and long-lasting potentiation of two 5-hydroxytryptophan-induced effects in mice by three selective 5-HT uptake inhibitors. Eur J Pharmacol 47:351–358CrossRefGoogle Scholar
  92. 14.
    Magnussen I, Tonder K, Engback F (1982) Paroxetine, a potent selective long-acting inhibitor of synaptosomal 5-HT uptake in mice. J Neural Transm 55:217–226CrossRefGoogle Scholar
  93. 15.
    Hyttel J, Larsen J-J (1985) Serotonin-selective antidepressants. Acta Pharmacol. Toxicol 65(Suppl 1): 146–153Google Scholar
  94. 16.
    Sulser F (1983) Mode of action of antidepressant drugs. J Clin Psychiat 44(Sec 2): 14–20Google Scholar
  95. 17.
    Sulser F (1983) Deamplification of noradrenergic signal transfer by antidepressants: A unified catecholamine-sertonin hypothesis of affective disorders. Psychopharmacol Bull 19:300–304PubMedGoogle Scholar
  96. 18.
    Blier P, Chaput Y, de Montigny C (1990) Pre-and postsynaptic modifications of the serotonin system by longterm antidepressant treatments: electrophysiological studies in the rat brain. Abstract from Proceedings of 17th CINP Congress, Kyoto: 10–14 Sep.Google Scholar
  97. 19.
    Nelson DR, Palmer KJ, Johnson AM (1990) Differential effects of paroxetine and desipramine on β-adrenoceptor number and function in rat cortex. Abstract from Proceedings of 17th CINP Congress, Kyoto: 10–14 Sep.Google Scholar
  98. 20.
    Lund J, Lomholt B, Fabricius J, Christensen JA, Bechgaard E (1979) The pharmacokinetics and the effect on blood 5-HT of paroxetine in man. Nordisk Psykiatrisk Tidsskrift 33:450–454CrossRefGoogle Scholar
  99. 21.
    Greb WH, Brett MA, Buscher G, Dierdorf H-D, von Schrader HW, et al. (1989) Absorption of paroxetine under various dietary conditions and following antacid intake. Acta Psychiat Scand 80:99–101CrossRefGoogle Scholar
  100. 22.
    Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TCG, et al. (1989) A review of the metabolism and pharmacokinetics of paroxetine in man. Acta Psychiat Scand 80:60–75CrossRefGoogle Scholar
  101. 23.
    Haddock RE, Johnson AM, Langley PF, Nelson DR, Pope JA, et al. (1989) Metabolic pathway of paroxetine in animals and man and the comparative pharmacological properties of is metabolites. Acta Psychiat Scand 80:24–26CrossRefGoogle Scholar
  102. 24.
    Bayer AJ, Roberts NA, Allen EA, Horan M, Routledge PA, et al. (1989) The pharmacokinetics of paroxetine in animals and man and the comparative pharmacological properties of is metabolites. Acta Psychiat Scand 80:85–86CrossRefGoogle Scholar
  103. 25.
    Ghose K (1989) The pharmacokinetics of paroxetine in elderly depressed patients. Acta Psychiat Scand 80:87–88CrossRefGoogle Scholar
  104. 26.
    Hebenstreit GF, Feilerer K, Zöchling R, Zentz A, Dunbar GC (1989) A pharmacokinetic dose titration study in adult and elderly depressed patients. Acta Psychiat Scand 80:81–84CrossRefGoogle Scholar
  105. 27.
    Doyle GD, Laher M, Kelly JG, Byrne MM, Clarkson A, et al. (1989) The pharmacokinetics of paroxetine in renal impairment. Acta Psychiat Scand 80:89–90CrossRefGoogle Scholar
  106. 28.
    Krastev Z, Terziivanov D, Vlahov V, Maleev A, Greb WH et al. (1989) The pharmacokinetics of paroxetine in patients with liver cirrhosis. Acta Psychiat Scand 80:91–92CrossRefGoogle Scholar
  107. 29.
    Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JGC (1989) Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin and digoxin. Acta Psychiat Scand 80:102–106CrossRefGoogle Scholar
  108. 30.
    Greb WH, Buscher G, Dierdorf H-D, Köster FE, Wolf D, et al. (1989) The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine. Acta Psychiat Scand 80:95–98CrossRefGoogle Scholar
  109. 31.
    Marley E, Wozniak KM (1983) Clinical and experimental aspects of interactions between amine oxidase inhibitors and amine re-uptake inhibitors. Psychol Med 13:735–749PubMedCrossRefGoogle Scholar
  110. 1.
    McGuick PR, Jefson MR, Mann DD et al (1992) J Med Chem 35:611–620CrossRefGoogle Scholar
  111. 2.
    Pharmeuropa (1996) 8:211-212Google Scholar
  112. 1.
    Pento JT (1994) Drags Fut 19:838–840Google Scholar
  113. 1.
    Burnham NL (1994) Polymers for delivering peptides and proteins. Am J Hosp Pharm 15:51 (2)Google Scholar
  114. 2.
    Alfieri DR (1995) Pegaspargase. Pediatr Nurs 21(5):471–474Google Scholar
  115. 1.
    Drags Fut (1995) 20:1292Google Scholar
  116. 2.
    Drags Fut (1990) 15:1184-1190Google Scholar
  117. 1.
    Tinkelman DG, Berkowitz RB (1991) A pilot study of pemirolast in patients with seasonal allergic rhinitis. Ann Allergy 66:162–165PubMedGoogle Scholar
  118. 2.
    Mar31, S. 1445Google Scholar
  119. 1.
    Choudary BM, Green GR, Grinter TJ, MacBeath FS, Parratt MJ (1994) Nucleosides Nucleotides 13:979–996CrossRefGoogle Scholar
  120. 2.
    Grinter TJ, Green GR, Parratt MJ (1989) Eur Pat Appl, zit. nach CA 112:7269Google Scholar
  121. 3.
    Harnden MR, Jarvest RL, Boyd MR, Sutton D, Vere Hodge RA (1989) J Med Chem 32:1738–1743PubMedCrossRefGoogle Scholar
  122. 4.
    Harnden MR, Jarvest RL, Bacon TH, Boyd MR (1987) J Med Chem 30:1636–1642PubMedCrossRefGoogle Scholar
  123. 5.
    Fowles SE, Pierce DM (1989) Analyst 114:1373–1375PubMedCrossRefGoogle Scholar
  124. 6.
    Goodwin CJ (1993) Anal Proc (London) 30:361; Ref. A.A. (1994) 56:2G42CrossRefGoogle Scholar
  125. 1.
    Hodge RA, Perkins RM (1989) Mode of action of 9-(4-hydroxy-3-hydroxymethylbut-l-yl)guanine (BRL 39123) against herpes simplex virus in MRC-5 cells. Antimicrob Agents Chemother 33:223–229PubMedCrossRefGoogle Scholar
  126. 2.
    SmithKline-Beecham 80791 München (1996) Fachinformation Vectavir* CremeGoogle Scholar
  127. 3.
    Spruance SL, Rea TL, Thoming C, Tucker R, Saltzmann R, Boon R (1997) Penciclovir cream for the treatment of herpes simplex labialis. A randomized, multicenter, double-blind, placebo-controlled trial. Topical Penciclovir Collaborative Study Group. JAMA 277:1374–1379PubMedCrossRefGoogle Scholar
  128. 4.
    Lavender EA, Laroche JP, MacLennan AI, Amos HE (1996) Dermal tolerance of penciclovir 5 % cream compared with placebo and aciclovir 5 % cream in healthy volunteers. Clinical dermatology 2000 Vancouver: Abstract P454Google Scholar
  129. 1.
    Drugs Fut (1990) 15(4):352-353Google Scholar
  130. 1.
    Kelly WB, Howie MB, Romanelli VA, Duarte JA, Rezaei H, McSweeney TD (1994) A comparison of pentamorphone and fentanyl in balanced anaesthesia during general surgery. Can J Aneaesth 41:703–709CrossRefGoogle Scholar
  131. 2.
    Wong HY, Parker RK, Fragen R, White PF (1991) Pentamorphone for managment of postoperative pain. Anesth Analg 72:656–660PubMedGoogle Scholar
  132. 1.
    Ebel S, Dorner W (1988) Jahrbuch Chemielabor 1988, VCH Verlagsgesellschaft mbH, Weinheim, S. 121Google Scholar
  133. 1.
    Moffat AC (Hrsg.) (1986) Clarke’s Isolation and Identification of Drugs, The Pharmaceutical Press, LondonGoogle Scholar
  134. 1.
    Mar 30, S. 1230Google Scholar
  135. 1.
    Joseph K, Stapp J, Reinecke J, Skamel HJ, Hoffken H, Benning R, Neuhaus C, Lenze H, Trautmann ME, Arnold R (1993) Rezeptorszintigraphie mit 111 In-Pentreotid bei endokrinen gastroenteropankreatischen Tumoren; Nuklearmedizin 32(6):299–305PubMedGoogle Scholar
  136. 2.
    Breeman WAP, Kwekkeboom DJ, Kooij PPM, Bakker WH, Hohland LJ, Visser TJ, Ensing GJ, Lamberts SWJ, Krenning EP (1995) Effect of dose and specific activity on tissue distribution of Indium-111-Pentetreotide in rats; J Nucl Med 36(4):623–627PubMedGoogle Scholar
  137. 1.
    Morgan DJ (1959) Chemlnd: 854-855Google Scholar
  138. 2.
    Haken JK, Hartley HNT, Srisukh D (1983) Chromatographia 17:589–596CrossRefGoogle Scholar
  139. 1.
    Takita T, Fujii A, Fukuoka T, Muraoka Y, Yoshioka O, Umezawa H (1979) Patent Nippon Kayaku KK: DE 2828933 / Brit 2001962 / Can 1078831 / Fr 2396021 / Jpn K 79 14980 / und 79 63089 / Neth Appl 7806947 / US 4195018, zit. nach CA(1979) 91: 74902Google Scholar
  140. 2.
    Thorpe PJ (1981) Drugs Fut 6:101–103Google Scholar
  141. 3.
    Tanaka W, Takita T (1979) Heterocycles 13:469–476CrossRefGoogle Scholar
  142. 4.
    Takita T, Muraoka Y, Nakatani T, Fujii A, Iitaka Y, Umezawa H (1978) J Antibiot 31:1073–1077PubMedCrossRefGoogle Scholar
  143. 5.
    Takahashi K, Ekimoto H, Aoyagi S, Koyu A, Kuramochi H, Yoshioka O et al. (1979) J Antibiot 32:36–42PubMedCrossRefGoogle Scholar
  144. 6.
    Saito S, Umezawa Y, Morishima H et al. (1982) THL 23:529–532Google Scholar
  145. 7.
    Takita T, Umezawa Y, Saito S et al. (1982) THL 23:521–524Google Scholar
  146. 1.
    Kurokawa H, Miura K, Yamashita Y et al. (1997) Gan Tokagaku-Ryoho 24:1273–78Google Scholar
  147. 2.
    Mar 31, S. 594Google Scholar
  148. 1.
    Schnoy N, Pfannkuch F, Beisbarth H (1979) Anaesthesist 28:503–510PubMedGoogle Scholar
  149. 2.
    Groß U, Rüdiger S, Kolditz L, Reichelt H (1990) Nachr Chem, Tech Lab 38:1461–1465CrossRefGoogle Scholar
  150. 3.
    Schulz-Schönhagen D, Seppelt K (1980) Medizin in unserer Zeit 4:77–81Google Scholar
  151. 4.
    Lowe KC (1984) The Pharmaceutical Journal 73-78Google Scholar
  152. 5.
    Lowe KC (1991) Adv Mater 3:87–93CrossRefGoogle Scholar
  153. 6.
    Meinert H, Fackler R, Knoblich A, Mader J, Reuter P, Röhlke W (1992) Biomat Art Cells & Immob Biotech 20:805–818Google Scholar
  154. 7.
    Müller U, Dietrich P, Prescher D (1983) J Chromatogr 259:243–254CrossRefGoogle Scholar
  155. 8.
    O’Mahony TKP, Cox AP, Roberts DJ (1993) J Chromatogr 637:1–11CrossRefGoogle Scholar
  156. 9.
    Begley P, Foulger B, Simmonds P (1988) J Chromatogr 445:119–128PubMedCrossRefGoogle Scholar
  157. 10.
    Holzgrabe U, Diehl B, Wawer J (1998) J Biomed Pharm Anal, in pressGoogle Scholar
  158. 1.
    Faithfull NS (1992) Oxygen delivery from fluorocarbon emulsions — aspects of convective and diffusive transport. Biomater Artif Cells Immobilization Biotechnol 20:797–804PubMedGoogle Scholar
  159. 2.
    Bando K, Teramoto S, Tago M, Seno S, Murakami T, Nawa S, Senoo Y (1988) Oxygenated perfluorocarbon, recombinant human Superoxide dismutase, and catalase ameliorate free radical induced myocardial injury during heart preservation and transplantation. J Thorac Cardiovasc Surg 96:930–938PubMedGoogle Scholar
  160. 3.
    Hale SL, Hammermann H, Kloner RA (1995) Effect of two perfluorocarbon emulsions on reperfusion injury after coronary artery occlusion in rabbits. Basic Res Cardiol 90:404–409PubMedCrossRefGoogle Scholar
  161. 4.
    Flaim SF (1994) Pharmacokinetics and side effects of perfluorocarbon-based blood substitutes. Artif Blood Substit Immobil Biotechnol 22:1043–1054CrossRefGoogle Scholar
  162. 5.
    Mattrey RF, Andre MP (1984) Ultrasonic enhancement of myocardial infarction with perfluorocarbon compounds in dogs. Am J Cardiol 54:206–210PubMedCrossRefGoogle Scholar
  163. 6.
    Mattrey RF, Long DC (1988) Potential role of PFOB in diagnostic imaging. Invest Radiol 23:S298–301PubMedCrossRefGoogle Scholar
  164. 7.
    Waxman K (1986) Perfluorocarbons as blood substitutes. Ann Emerg Med 15:1423–1424PubMedCrossRefGoogle Scholar
  165. 8.
    Liu MS, Dobben GD, Szanto PB, Alrenga DP, Khin U, Arambulo AS, Forrest R (1976) Myelography with perfluoroctylbromide. Comparison with Pantopaque. Invest Radiol 11:319–330PubMedCrossRefGoogle Scholar
  166. 9.
    Mattrey RF (1994) The potential role of perfluorochemicals (PFCs) in diagnostic imaging. Artif Cells Blood Substit Immobil Biotechnol 22:295–313PubMedCrossRefGoogle Scholar
  167. 10.
    Waxman K, Tremper KK, Cullen BF, Mason GR (1984) Perfluorocarbon infusion in bleeding patients refusing blood transfusions. Arch Surg 119:721–724PubMedCrossRefGoogle Scholar
  168. 11.
    Atabek U, Spence RK, Pello M, Alexander J, Camishion R (1992) Pancreaticoduodenectomy without homologous blood transfusion in an anemic Jehovah’s Witness. Arch Surg 127:349–351PubMedCrossRefGoogle Scholar
  169. 12.
    Chen HS, Yang ZH (1988) Perfluorocarbon as blood substitute in clinical applications and in war casualties. Biomater Artif Cells Artif Organs 16:403–409PubMedGoogle Scholar
  170. 13.
    Reindorf CA, Kurantsin-Mills J, Allotey JB, Castro O (1985) Perfluorocarbon compounds: effects on the rheological properties of sickle erythrocytes in vitro. Am J Hematol 19:229–236PubMedCrossRefGoogle Scholar
  171. 14.
    Magovern GJ Jr., Flaherty JT, Gott VL, Bulkley BH, Gardner TJ (1982) Optimal myocardial protection with fluosol cardioplegia. Ann Thorac Surg 34:249–257PubMedCrossRefGoogle Scholar
  172. 15.
    Oldham KT, Guice KS, Gore D, Gourley WK, Lobe TE (1987) Treatment of intestinal ischemia with oxygenated intraluminal perfluorocarbons. Am J Surg 153:291–294PubMedCrossRefGoogle Scholar
  173. 16.
    Jaffe CC, Wohlgelernter D, Cabin H, Bowman L, Deckelbaum L, Remetz M, Cleman M (1988) Preservation of left ventricular ejection fraction during percutaneous transluminal coronary angioplasty by distal transcatheter coronary perfusion of oxygenated Fluosol DA 20 %. Am Heart J 115:1156–1164PubMedCrossRefGoogle Scholar
  174. 17.
    Tutuncu AS, Akpir K, Mulder P, Faithfull NS, Erdmann W, Lachmann B (1992) Gas exchange and lung mechanics during long-term mechanical ventilation with intratracheal perfluorocarbon administration in respiratory distress syndrome. Adv Exp Med Biol 317:401–407PubMedCrossRefGoogle Scholar
  175. 18.
    Degraeuwe PL, Vos GD, Blanco CE (1995) Perfluorochemical liquid ventilation: from the animal laboratory to the intensive care unit. Int J Artif Organs 18:674–683PubMedGoogle Scholar
  176. 19.
    Tooley R, Hirschl RB, Parent A, Bartlett RH (1996) Total liquid ventilation with perfluorocarbons increases pulmonary end-expiratory volume and compliance in the setting of lung atelectasis. Crit Care Med 24:268–273PubMedCrossRefGoogle Scholar
  177. 20.
    Spiess BD, McCarthy RJ, Tuman KJ, Woronowicz AW, Tool KA, Ivankovich AD (1988) Treatment of decompression sickness with a perfluorocarbon emulsion (FC-43). Undersea Biomed Res 15:31–37PubMedGoogle Scholar
  178. 21.
    Spiess BD, Braverman B, Woronowicz AW, Ivankovich AD (1986) Protection from cerebral air emboli with perfluorocarbons in rabbits. Stroke 17:1146–1149PubMedCrossRefGoogle Scholar
  179. 22.
    Bowman RJ (1983) Red blood cell substitues and artificial blood. Hum Pathol 14:218–220PubMedCrossRefGoogle Scholar
  180. 23.
    Campbell BH, Janjan NA, Byhardt RW, Toohill RJ (1990) Treatment-related toxicities with Fluosol-DA 20 % infusion during radiation in advanced head and neck malignancies. Laryngoscope 100:237–239PubMedCrossRefGoogle Scholar
  181. 24.
    Rockwell S, Kelley M, Irvin CG, Hughes CS, Porter E, Yabuki H, Fischer JJ (1991) Modulation of tumor oxygenation and radiosensitivity by a perfluorooctylbromide emulsion. Radiother Oncol 22:92–98PubMedCrossRefGoogle Scholar
  182. 25.
    Lincoff H, Kreissig I, Brodie S, Wilcox L (1982) Expanding gas bubbles for the repair of tears in the posterior pole. Graefes Arch Clin Exp Ophtalmol 219:193–197CrossRefGoogle Scholar
  183. 26.
    Korobelnik JF, Nabet L, Frau E, Elmaleh C, Hanna K, Pouliquen Y (1992) Use of perfluorocarbon solutions in the surgical treatment of posterior luxation of the lens. J Fr Ophtalmol 15:235–242PubMedGoogle Scholar
  184. 27.
    Kreissig I (1988) Gas-no touch-Enucleation. Klin Monatsbl Augenheilk 193:489–492CrossRefGoogle Scholar
  185. 28.
    Desai UR, Peyman GA, Chen CJ, Nelson NC Jr, Alturki WA, Blinder KJ, Paris CL (1992) Use of perfluoroperhydrophenanthrene in the managment of suprachorioidal hemorrhages. Ophthalmology 99:1542–1547PubMedGoogle Scholar
  186. 29.
    Wootton SL, Coley BD, Hilton SVW, Edwards DK III, Amberg JR, Mattrey RF (1993) Value of brominated fluorocarbons for the radiographic diagnosis of small-bowel obstruction: Comparison with other contrast agents in rats. Amer J Radiol 161:409–416Google Scholar
  187. 30.
    Enzmann DR, Young S (1981) Arthrography using perfluorocarbon compounds. Invest Radiol 16:46–49PubMedCrossRefGoogle Scholar
  188. 31.
    Long DM, Nielson MD, Mutter FK, Lasser EC, Liu MS, Russell S (1979) Comparison of radiopaque perfluorocarbon and ethiodol in lymphography. Radiology 133:71–76PubMedGoogle Scholar
  189. 32.
    Mattrey RF, Shelton RE, Strich GM (1985) Fluosol as an Ultrasound Contrast Agent for Hepatic Tumor Detection: Clinical Results. Invest Radiol 20:S49CrossRefGoogle Scholar
  190. 33.
    Arellano R, Mattrey RF, Steinbach G, Baker KG (1992) Effect of Formulation on the Ultrasound (US) Properties of Perfluorocarbon (PFC) Emulsions. Invest Radiol 27:1088CrossRefGoogle Scholar
  191. 34.
    Satterfield R, Tarter VM, Schumacher DJ, Tran P, Mattrey RF (1993) Comparison of Different Perfluorocarbons as Ultrasound Contrast Agents. Invest Radiol 28:325–331PubMedCrossRefGoogle Scholar
  192. 35.
    Shelton RE, Mattrey RF, Ogino MT, Johnson KK, Mitten RM (1985) Effect of Time, Ringers and Perfluorocarbon Compounds on the Echogenicity of Myocardial Infarcts. Invest Radiol 20:S49CrossRefGoogle Scholar
  193. 36.
    Sartoris DJ, Guerra J Jr., Mattrey RF, Resnick D, Haghighi P, Mitten R, Trudell D, Pate D (1986) Perfluorooctylbromide as a contrast agent for computed tomographic imaging of septic and aseptic arthritis. Invest Radiol 21:49–55PubMedCrossRefGoogle Scholar
  194. 37.
    Patronas NJ, Hekmatpanah DK (1983) Brain-tumor imaging using radiopaque perfluorocarbon: A preliminary report. J Neurosurg 58:650–653PubMedCrossRefGoogle Scholar
  195. 38.
    Eidelberg D, Johnson G, Barnes D, Tofts PS, Delphy D, Plummer D, McDonald WI (1988) 19F NMR imaging of blood oxygenation in the brain. Magn Reson Med 6:344–352PubMedCrossRefGoogle Scholar
  196. 39.
    Wolf GL (1994) Technical improvements in the staging of cancer: the role of imaging and contrast agents. Artif Cells Blood Substit Immobil Biotechnol 22:285–294PubMedCrossRefGoogle Scholar
  197. 40.
    Low RN, Carter WD, Saleh F, Sigeti JS (1995) Ovarian cancer: comparison of findings with perfluorocarbon-enhanced MR imaging, In-111-CYT-103 immunoscintigraphy, and CT. Radiology 195:391–400PubMedGoogle Scholar
  198. 41.
    Rubin DL, Muller HH, Nino Murcia M, Sudhu M, Christy V, Young SW (1991) Intraluminal contrast enhancement and MR visualization of the bowel wall: efficacy of PFOB. J Magn Reson Imaging 1:371–380PubMedCrossRefGoogle Scholar
  199. 42.
    Sotak CH, Hees PS, Huang HN, Hung MH, Krespan CG, Raynolds S (1993) A new perfluorocarbon for use in fluorine-19 magnetic resonance imaging and spectroscopy. Magn Reson Med 29:188–195PubMedCrossRefGoogle Scholar
  200. 43.
    Thomas SR, Clark LC Jr., Ackerman JL, Pratt RG, Hoffmann RE, Busse LJ, Kinsey RA, Samaratunga RC (1986) MR Imaging of the lung using liquid perfluorocarbons. J Comput Assist Tomogr 10:1–9PubMedCrossRefGoogle Scholar
  201. 44.
    Mason RP, Shukla H, Antich PP (1993) In vivo oxygen tension and temperature: simultaneous determination using 19F NMR spectroscopy of perfluorocarbon. Magn Reson Med 29:296–303PubMedCrossRefGoogle Scholar
  202. 45.
    Fuhrman BP, Hernan LJ, Holm BA, Leach CL, Papo MC, Steinhorn DM (1994) Perfluorocarbon associated gas exchange (PAGE): gas ventilation of the perfluorocarbon filled lung. Artif Cells Blood Substitut Immobil Biotechnol 22:1133–1139CrossRefGoogle Scholar
  203. 46.
    Vercellotti GM, Hammerschmidt DE, Craddock PR, Jacob HS (1982) Activation of plasma complement by perfluorocarbon artificial blood: probable mechanism of adverse pulmonary reactions in treated patients and rationale for corticosteroids prophylaxis. Blood 59:1299–1304PubMedGoogle Scholar
  204. 47.
    Mattrey RF, Strich G, Shelton RE, Gosink BB, Leopold GR, Lee T, Forsythe J (1987) Perfluorochemicals as US contrast agents for tumor imaging and hepatosplenography: preliminary clinical results. Radiology 163:339–343PubMedGoogle Scholar
  205. 48.
    Goodman RL, Moore RE, Davis ME, Stokes D, Yuhas JM (1984) Perfluorocarbon emulsion in cancer therapy: preliminary observations on presently available formulations. Int J Radiat Oncol Biol Phys 10:1421–1424PubMedCrossRefGoogle Scholar
  206. 49.
    Golubev AM, Vasilev AE, Shibaev NV, Maevskii El, Islamov BI (1982) Morphological analysis of the rat organs after massive blood substitution with perfluorotributylamine emulsion. Arkh Patol 44:55–60PubMedGoogle Scholar
  207. 50.
    Triolo AJ, Osterholm JL, Kratky MT (1989) Enhancement of the Arthus reaction and suppression of delayed type hypersensitivity (DTH) by pluronic F-68, a detergent frequently used to prepare perfluorocarbon emulsions. Int J Immunopharmacol 11:241–248PubMedCrossRefGoogle Scholar
  208. 51.
    Hammerschmidt DE, Vercellotti GM (1988) Limitation of complement activation by perfluorocarbon emulsions: superiority of lecithin-emulsified preparations. Biomater Artif Cells Artif Organs 16:431–438PubMedGoogle Scholar
  209. 52.
    Lane TA, Lamkin GE (1986) Increased infection mortality and decreased neutrophil migration due to a component of an artificial blood substitute. Blood 68:351–354PubMedGoogle Scholar
  210. 53.
    Babbitt DG, Forman MB, Jones R, Bajaj AK, Hoover RL (1990) Prevention of neutrophil-mediated injury to endothelial cells by perfluorochernical. Am J Pathol 136:451–459PubMedGoogle Scholar
  211. 54.
    Chilcoat RT, Gerson JI, Allen FB, Mapleson WW (1985) The effect of Fluosol-DA on induction of inhalation anesthesia. Anesth Analg 64:405–410PubMedCrossRefGoogle Scholar
  212. 55.
    Hammarstrom M, Mullins R, Sgoutas D (1983) Effect of Fluosol DA on radioimmunoassay results. Clin Chem 29:1418–1421PubMedGoogle Scholar
  213. 56.
    Brahme F, Sovak M, Powell H, Long DM (1976) Perfluorocarbon bromides as contrast media in radiography of the central nervous system. Acta Radiol [Suppl] (Stockh) 347:347–459Google Scholar
  214. 57.
    Peyman GA, Schulman JA, Sullivan B (1995) Perfluorocarbon liquids in ophthalmology. Surv Ophthalmol 39:375–395PubMedCrossRefGoogle Scholar
  215. 58.
    Sanfilippo B, Ciardiello F, Salomon DS, Kidwell WR (1988) Growth of cells on a perfluorocarbon-medium interphase: a quantitiative assay for anchorage-independent cell growth. In Vitro Cell Dev Biol 24:71–78PubMedCrossRefGoogle Scholar
  216. 59.
    Moreira H, de Queiroz JM Jr., Liggett PE, McDonnell PJ (1992) Corneal toxicity study of two perfluorocarbon liquids in rabbit eyes. Cornea 11:376–379PubMedCrossRefGoogle Scholar
  217. 1.
    Drugs Fut (1981) 6(4):231-233Google Scholar
  218. 1.
    Sprankle DJ, Jensen EC (1992) Ana 21:375–413Google Scholar
  219. 2.
    Kennedy JH (1997) Org Process Res Dev 1:68–71CrossRefGoogle Scholar
  220. 1.
    Oberdisse E, Hackenthal E, Kuschinski K (Hrsg.) (1997) Pharmakologie und Toxikologie, Springer-Verlag, Berlin HeidelbergGoogle Scholar
  221. 2.
    Baas H, Deuschl G, Oertel W, Poewe W (1997) Deutsch Apoth Ztg 137, 860–866Google Scholar
  222. 3.
    Seeman P, Van Tol HM (1994) Trends Pharmacol Sci 15, 264–270PubMedCrossRefGoogle Scholar
  223. 4.
    Fuller RW, Clemens JA (1991) Life Sci 49, 925–934PubMedCrossRefGoogle Scholar
  224. 5.
    Missale C, Nash SR, Ribonson SW, Jaber M, Caron MC (1998) Physiol Rev 78, 189–225PubMedGoogle Scholar
  225. 6.
    Pulvirenti L, Koob GF (1994) Trends Pharmacol Sci 15, 374–379PubMedCrossRefGoogle Scholar
  226. 7.
    Sem O (1994) New Engl J Med 331, 942–944CrossRefGoogle Scholar
  227. 1.
    Keller K, Greiner S, Stockebrand P (1992) Homöopathische Arzneimittel, Govi-Verlag: Bd. 3Google Scholar
  228. 1.
    Keller K, Greiner S, Stockebrand PHorn. AM, Govi-Verlag: Bd. 3Google Scholar
  229. 2.
    DHU, Karlsruhe (1994) S. 228-229Google Scholar
  230. 3.
    Voisin H (1969) Materia medica des hom. Praktikers Haug-Verlag Heidelberg: S. 944–947Google Scholar
  231. 1.
    Keller K, Greiner S, Stockebrand P (1992) Homöopathische Arzneimittel, Govi-Verlag, Bd. 3Google Scholar
  232. 1.
    Bockmühl M, Ehrhart G (1949) Liebigs Ann Chem 561:52–85CrossRefGoogle Scholar
  233. 2.
    Attenburrow J, Elks J, Hems BA, Speyer KN (1949) J Chem Soc 510-518Google Scholar
  234. 3.
    Müller RK (1976) Die tox.-chem. Analyse, Verlag Chemie, Weinheim, S. 428Google Scholar
  235. 4.
    Clarke ECG (1969) Isolation and Identification of Drugs, The Pharmaceutical Press, London, S. 478Google Scholar
  236. 5.
    Shaw WHC, Jefferies JP (1951) J Pharmacol 3:823–828CrossRefGoogle Scholar
  237. 6.
    Hansch C (Hrsg.) (1990) Comprehensive Medicinal Chemistry, Vol. 6, Pergamon Press, OxfordGoogle Scholar
  238. 7.
    Jane I, McKinnon A, Flanagan RJ (1985) J Chromatogr 323:191–225PubMedCrossRefGoogle Scholar
  239. 8.
    Wheals BB (1980) J Chromatogr 187:6–85Google Scholar
  240. 9.
    Levi L, Farmilo CG (1952) Can J Chem 30:793–799CrossRefGoogle Scholar
  241. 1.
    Kalir A, Edery H, Pelah Z, Balderman D, Porath G (1969) J Med Chem 12:473–477PubMedCrossRefGoogle Scholar
  242. 2.
    Jones LA, Beaver RW, Schmoeger TL, Ort JF, Leander JD (1981) J Org Chem 46:3330–3333CrossRefGoogle Scholar
  243. 3.
    Moffat AC (1986) Clarke’s Isolation and Identification of Drugs, Pharmaceutical Press, LondonGoogle Scholar
  244. 4.
    Johnson PY, Pan R, Wen JQ, Halfman CJ (1981) J Org Chem 46:2049–2054CrossRefGoogle Scholar
  245. 5.
    Brine GA, Williams EE, Boldt KG, Carroll FI (1979) J Heterocyclic Chem 16:1425–1429CrossRefGoogle Scholar
  246. 6.
    Masoud AN (1976) J Pharm Sci 65:1585–1589PubMedCrossRefGoogle Scholar
  247. 7.
    Cone EJ, Buchwald W, Yousefnejad D (1981) J Chromatogr 223:331–339PubMedCrossRefGoogle Scholar
  248. 1.
    Mar 31, S. 1470Google Scholar
  249. 2.
    O’Brien CP (1995) Drug Addiction and Drug Abuse. In: The Pharmacological Basis of Therepeutics, 9th Edition, S 574–575, Molinoff PB, Hardmann JG, Limbird LE, Ruddon RW, Goodman-Gilman A eds, McGraw-Hill, New YorkGoogle Scholar
  250. 1.
    Widman O (1893) Ber dt Chem Ges 26:2612–2621CrossRefGoogle Scholar
  251. 2.
    Muenster G (1979) Ger Offen 2,819,046; zit. nach CA (1979) 91:211119nGoogle Scholar
  252. 3.
    Beil H15, 287-291Google Scholar
  253. 4.
    Chateau-Gosselin M, Christian GD, Patriarche GJ (1979) Mikrochim Acta 1:415–421CrossRefGoogle Scholar
  254. 5.
    Verma BC, Sharma DK, Kumar S, Jamwal VS et al. (1990) Nat Acad Sci Lett (India) 13:269–272; zit. nach CA (1991) 115:197422mGoogle Scholar
  255. 6.
    Chateau-Gosselin M, Patriarche GJ (1978) Anal Chim Acta 102:215–220; zit. nach CA (1979) 90:92500xCrossRefGoogle Scholar
  256. 7.
    Billabert A, Hamon M (1977) Analysis 5(3):122–126; zit. nach CA (1977) 87:11698fGoogle Scholar
  257. 8.
    Merck-Schuchard KatalogGoogle Scholar
  258. 1.
  259. 1.
    Weiss R (1943) Org Synth, Coll Vol 2:61–62Google Scholar
  260. 2.
    Nathanson F (1893) Chem Ber 26:2576–2583CrossRefGoogle Scholar
  261. 3.
    Bergmann ED, Heller A, Weiler-Feilchenfeld H (1959) Bull Chim Soc Fr, S. 635-637Google Scholar
  262. 4.
    Dieckmann W (1914) Chem Ber 47:1435–1440CrossRefGoogle Scholar
  263. 5.
    Klosa J (1954) Arch Pharm 287:323–326CrossRefGoogle Scholar
  264. 6.
    Moffat AC (Hrsg.) (1986) Clarke’s Isolation and Identification of Drugs, The Pharmaceutical Press, London, S.880Google Scholar
  265. 7.
    Pouchert CJ (1985) The Aldrich Library of FT-IR Spectra, Aldrich Chemical, Milwaukee, Bd. 1(2), S.55Google Scholar
  266. 8.
    Rosenfeld MJ, Ravi Shankar BK, Shechter H (1988) J Org Chem 53:2699–2705CrossRefGoogle Scholar
  267. 9.
    Steigel A, Veith RW, Braun M (1989) Liebigs Ann Chem, S. 99-101Google Scholar
  268. 10.
    Hansch C, Sammes PG, Taylor JB (Hrsg.) (1990) Comprehensive Medicinal Chemistry, Pergamon Press, Oxford, Bd. 6, S.768Google Scholar
  269. 1.
    Mar31, S.927Google Scholar
  270. 1.
    Harfst G, Katzung K, Sahihi A (1991) Rauschgift-Szene-Jargon von A-Z, Holger Harfst Verlag, WürzbugGoogle Scholar
  271. 2.
    USP 2835669 (1958) Thomae, Wick (Boehringer); Schweizer Pat. 318638 (1953) C.H. BoehringerGoogle Scholar
  272. 3.
    USP 3074941 (1963) Kalm MJ (Searle & Co.), zit. nach CA (1963) 59:10069hGoogle Scholar
  273. 4.
    Klosa J (1963) J Parkt Chem 21:1–11CrossRefGoogle Scholar
  274. 5.
    Clarke FH (1962) J Org Chem 27:3251–3253CrossRefGoogle Scholar
  275. 6.
    Bohn G, Rücker G, Kröger H (1976) Arch Toxicol 35:213–220PubMedCrossRefGoogle Scholar
  276. 7.
    Unterhalt B (1974) Dtsch Apoth Ztg 114(27):1017–1020Google Scholar
  277. 8.
    Alm S, Bomgren B, Boren HB, Karlsson H et al. (1982) Forensic Sci Int 19(3):271–280PubMedCrossRefGoogle Scholar
  278. 9.
    Moffat AC (Hrsg.) (1986) Clarke’s Isolation and Identifaction of Drugs, 2. Aufl., The Pharmaceutical Press, LondonGoogle Scholar
  279. 10.
    Neuninger H (1987) Sci Pharm 55:1–11Google Scholar
  280. 11.
    Bohn G, Rücker G, Kröger H (1975) Beitr Gerichtl Med 34:117–122Google Scholar
  281. 12.
    Mrongovius R, Neugebauer M, Rücker G (1984) Eur J Med Chem — Chim Ther 2:161–166Google Scholar
  282. 13.
    Cartoni GP, Cavalli A, Giarusso A, Rosati F (1973) J Chromatogr 84:419–422PubMedCrossRefGoogle Scholar
  283. 1.
    Harfst G, Katzung K, Sahihi A (1991) Rauschgift-Szene-Jargon von A-Z; Holger Harfst Verlag, WürzburgGoogle Scholar
  284. 2.
    Clarke FH (1962) J Org Chem 27:3251–3253CrossRefGoogle Scholar
  285. 3.
    USP 2835669 (1958) Thomae, Wick (Boehringer)Google Scholar
  286. 4.
    Moffat AC (1986) Clarke’s Isolation and Identification of Drugs, 2. Aufl., The Pharmaceutical Press, LondonGoogle Scholar
  287. 1.
    Grüssner A, Hellerbach J, Schnider O (1957) Helv Chim Acta 40:1232–1241CrossRefGoogle Scholar
  288. 2.
    Clarke ECG (1969) Isolation and Identification of Drugs, 1. Aufl., The Pharmaceutical Press, London, S.488Google Scholar
  289. 3.
    Hansch C (1990) Comprehensive Medicinal Chemistry, 1. Aufl., Pergamon Press, Oxford, S. 769Google Scholar
  290. 4.
    Stead AH, Gill R, Wright T, Gibbs JP et al. (1982) Analyst 107:1106–1168PubMedCrossRefGoogle Scholar
  291. 5.
    Jane I, McKinnon A, Flanagan RJ (1985) J Chromatogr 323:191–225PubMedCrossRefGoogle Scholar
  292. 6.
    Gesetz über den Verkehr mit Betäubungsmitteln (1981) 28. Erg., 28.07.1981 (BGB1 I, S. 681), S.35Google Scholar
  293. 1.
    Pachler KGR, Matlock F, Gremlich HU (1988) Merck FTIR Atlas, Verlag Chemie, Weinheim, S. 625Google Scholar
  294. 2.
    Heilbron I, Bunburg HM, Cook AH, Jones ERH (1953) Dictionary of Organic Compounds, Bd. II, Eyre & Spottiswoode, London, S. 765Google Scholar
  295. 1.
    Bollag U (1982) Phenoxetol-chlorhexidine cream as a prophylactic antibacterial agent in burns. Lancet 1982:2:106CrossRefGoogle Scholar
  296. 2.
    Frohlich KW, Andersen LM, Knutsen A, et al (1984) Phenoxyethanol as a nontoxic substitute for fomaldehyde in long-term preservation of human anatomical specimens for dissection and demonstration purposes. Fundam Appl Toxicol 8:272–279Google Scholar
  297. 3.
    Fuursted K, Hjort A, Knudsen L (1997) Evaluation of bactericidal activity and lag of regrowth (postantibiotic effect) of five antiseptics on nine bacterial pathogens. J Anti-microb Chemother 40:221–226CrossRefGoogle Scholar
  298. 4.
    Gilbert P, Beveridge EG, Crone PB (1977) Inhibition of some respiration and dehydrogenase enzyme systems in Escherichia coli NCTC 5933 by phenoxyethanol. Microbios 20:29–37PubMedGoogle Scholar
  299. 5.
    Lowe I, Southern J (1994) The antimicrobial activity of phenoxyethanol in vaccines. Lett Appl Microbiol 18:115–116PubMedCrossRefGoogle Scholar
  300. 6.
    Mar 57:1142-1Google Scholar
  301. 7.
    Mitchell P, Powles R, Rege K, et al. (1993) Phenoxyethanol is effective topical therapy of gram-negative cellulitis in neutropenic patients. J Hosp Infect 25:53–56PubMedCrossRefGoogle Scholar
  302. 8.
    Roper CS, Howes D, Blain PG, et al. (1997) Percutaneous penetration of 2-phenoxyethanol through rat and human skin. Food Chem Toxicol 35:1009–1016PubMedCrossRefGoogle Scholar
  303. 9.
    Scortichini BH, Quast JF, Rao KS (1987) Teratologic evaluation of 2-phenoxyethanol in New Zealand White rabbits following dermal exposure. Funfdam Appl Toxicol 8:272–279CrossRefGoogle Scholar
  304. 10.
    Stickler DJ, Plant S, Bunni NH, et al. (1981) Some observations on the activity of three antiseptics used as bladder irrigants in the treatment of urinary tract infections in patients with indwelling catheters. Paraplegia 19:325–333PubMedCrossRefGoogle Scholar
  305. 11.
    Stickler DJ, Clayton CL, Chawla JC (1987) Assessment of antiseptic bladder washout procedures using a physical model of the catheterised bladder. Brit J Urol 60:413–418PubMedCrossRefGoogle Scholar
  306. 1.
    Schulz E, Sprung WD, Kröning G, Vietinghoff G (1978) Pharmazie 33:749–753PubMedGoogle Scholar
  307. 1.
    Rauch HJ, Elsken B (1948) Aerztl Wochenschr 3:631Google Scholar
  308. 1.
    J Chromatogr (1991) 585:259-266Google Scholar
  309. 2.
    J Chromatogr (1977) 134:359-364Google Scholar
  310. 3.
    J Chromatogr (1972) 70:206-209Google Scholar
  311. 1.
    Haseloff RF, Ebert B, Roeder B (1989) Generation of free radicals by photoexcitation of pheophorbide alpha, haematoporphyrin and protoporphyrin. J Photochem Photobiol-B. 3(4):593–602PubMedCrossRefGoogle Scholar
  312. 2.
    Iwai K, Ido T, Iwata R, Kawamura M, Kimura S (1989) Localizing efficiency of [48V]vanadylpheophorbide in tumor as a new tumor imaging agent. Int J Rad Appl Instrum B 16(8):783–789PubMedCrossRefGoogle Scholar
  313. 3.
    Yamashita Y, Moriyasu F, Ono S, Kimura T, Kajimura K, Someda H, Hamato N, Nabeshima M, Sakai M, Okuma M (1991) Photodynamic therapy using pheophorbide-a and Q-switched ND-L-YAG laser on implanted human hepatocellular cacinoma. Gastroenterol Jpn 26(5):623–627PubMedGoogle Scholar
  314. 4.
    Fujishima I, Sakai T, Tanaka T, Ryu H, Uemura K, Fujishima Y, Horiuchi K, Daikuzono N, Sekiguchi Y (1991) Photodynamic therapy using pheophorbide A and ND-LYAG-laser. Neurol Med Chir Tokyo 31(5):257–263PubMedCrossRefGoogle Scholar
  315. 1.
    Hartlapp G (1979) Monophosphorsäure. In: Bartholomé E, Biekert E, Hellmann H, Ley H et al. (Hrsg.) Ullmanns Encyclopädie der technischen Chemie, 4. Aufl., Verlag Chemie, Weinheim, Bd. 18, S. 308–319Google Scholar
  316. 2.
    Bauer G, Vogt W (1981) Anal Chem 53:917–919CrossRefGoogle Scholar
  317. 1.
    Mar 30, S. 1401Google Scholar
  318. 1.
    Keller K, Greiner S, Stockebrand P (1992) Homöopathische Arzneimittel, Govi-Verlag: Bd. 3Google Scholar
  319. 1.
    Keller K, Greiner S, Stockebrand P (1992) Homöopathische Arzneimittel, Govi-Verlag: Bd. 3Google Scholar
  320. 2.
    DHU, Karlsruhe (1994) S. 232-233Google Scholar
  321. 3.
    Voisin H (1969) Materia medica des hom. Praktikers, Haug-Verlag Heidelberg: S. 952–961Google Scholar
  322. 1.
    Mesley RJ, Houghton EE (1966) J Pharm Pharmacol 19:295–304CrossRefGoogle Scholar
  323. 2.
    Cobb PH, Hill GT (1976) J Chromatogr 123:444–447PubMedCrossRefGoogle Scholar
  324. 1.
    Kuzin MI, Pomelov VS, Vandiaev GK et al. (1983) Antibiotika 28:358–362Google Scholar
  325. 2.
    Turner AC (1983) Scand J Gastroenterol Suppl 84:106–110PubMedGoogle Scholar
  326. 1.
    DE 2520483, zit. nach CA (1976) 84:90007Google Scholar
  327. 2.
    Dubois MJ, Dubois J, Vezin JC, Cousse H (1977) Boll Chim Farm 116:520–529PubMedGoogle Scholar
  328. 3.
    Hansch C, Sammes PG, Talyor JB (Hrsg.) (1990) Comprehensive Medicinal Chemistry, Pergamon Press, Oxford, Bd. 6, S.774Google Scholar
  329. 4.
    Benard P, Rico AG, Braun JP, Burgart-Sacaze V et al. (1981) Boll Chim Farm 120:114–123PubMedGoogle Scholar
  330. 1.
    Drugs Fut (1984) 9(3):204-205Google Scholar
  331. 1.
    Zimmermann DM, Smits SE, Hynes MD, Cantrell BE, Leander JD, Mendelsohn LG, Nickander R (1985) Picenadol. Drug Alcohol Depend 14:381–401CrossRefGoogle Scholar
  332. 2.
    Goldstein DJ, Brunelle RL, George RE, Cooper SA, Desjardins PJ, Gaston GW, Jeffers GE, Gallegos LT, Reynolds DC (1994) Picenadol in a large multicenter dental pain study. Pharmacotherapy 14:54–59PubMedGoogle Scholar
  333. 3.
    Sherline DM (1983) Picenadol (LY 150720) compared with meperidine and placebo for relief of postcesarean section pain: a randomized double-blind study. Am J Obstet Gynecol 147:404–406PubMedGoogle Scholar
  334. 4.
    Franz PM, Anliker SL, Callaghan JT, de Sante KA, Dhahir PH, Nelson RL, Rubin A (1990) Disposition in humans of racemic picenadol, an opioid analgesic. Drug Metab Dispos 18:968–973PubMedGoogle Scholar
  335. 1.
    Mar31, S.929Google Scholar
  336. 1.
    Orzalesi G, Seilen R (1970) Fr Demande 2,100,850; zit. nach CA (1972) 77:164502fGoogle Scholar
  337. 2.
    Foresti E, Di Sanseverino LR, Sabatino P (1986) Acta Cryst C42:220–224Google Scholar
  338. 3.
    Fossati T, Parisi S; Abbiati G, Castiglioni C (1992) J Chromatogr 577:382–386PubMedCrossRefGoogle Scholar
  339. 1.
    Violi F, Ghiselli A, Luliano L, Pratico D, Allessandri C, Balsano F (1988) Inhibition by picotamide of thromboxane production in vitro and ex vivo. Eur J Clin Pharmacol 33:599–602PubMedCrossRefGoogle Scholar
  340. 2.
    Modesti PA, Colella A, Abbate R, Gensini G, Neri-Serneri G (1989) Competitive inhibition of platelet thromboxane A2 receptor binding by picotamide. Eur J Pharmacol 169:85–93PubMedCrossRefGoogle Scholar
  341. 3.
    Gresele P, Deckmyn H, Arnout J, Nenci GG, Vermylen J (1989) Characterization of N,N’-bis(3-picolyl)-4-methoxy-isophtalamide (picotamide) as a dual thromboxane synthase inhibitor/thromboxane A2 receptor antagonist in human platelets. Thromb Haemost 61:479–484PubMedGoogle Scholar
  342. 4.
    Berrettini M, De Cunto M, Parise P, Grasselli S, Nenci GG (1990) „In vitro“ and „ex vivo“ effects of picotamide, a combined thromboxane A2-synthase inhibitor and-receptor antagonist, on human platelets. Eur J Clin Pharmacol 39:495–500PubMedCrossRefGoogle Scholar
  343. 5.
    Cattaneo M, Tenconi PM, Lecchi A, Mannucci PM (1991) In vitro effects of picotamide on human platelets aggregation, the release reaction and thromboxane B2 production. Thromb Res 62:717–724PubMedCrossRefGoogle Scholar
  344. 6.
    Minuz P, Lechi C, Arosio E, Guzzo P, Zannoni M, Lauciello C, Lechi A (1991) Effect of picotamide on platelet aggregation and on thromboxane A2 production in vivo. Thromb Haemost 65:312–316PubMedGoogle Scholar
  345. 7.
    Neirotti M, Molaschi M, Ponzetto M, Macchione C, Poli L, Bonino F, Fabris F (1994) Hemodynamic, hemorheologic, and hemocoagulative changes after treatment with picotamide in patients affected by peripheral arterial disease (PAD) of the lower limbs. Angiology 45:137–141PubMedCrossRefGoogle Scholar
  346. 8.
    Coto V, Cocozza M, Oliviero U, Lucariello A, Picano T, Coto F, Cacciator L (1989) Clinical efficacy of picotamide in long-term treatment of intermittent claudication. Angiology 40:880–885PubMedCrossRefGoogle Scholar
  347. 9.
    Balsano F, Violi F (1993) Effect of picotamide on the clinical progression of peripheral vascular disease. A double-blind placebo-controlled study. The ADEP Group. Circulation 87:1563–1569PubMedCrossRefGoogle Scholar
  348. 10.
    Canonico V, Ammaturo V, Guarini P, Tedeschi C, Nunziata G, Nappi A, Forgione L, Rengo F (1991) Valutazione clinico-strumentale della efficacia della picotamide nel trattamento delle arteriopatie croniche ostruttive degli arti inferiori. Minerva Cardioangiol 39:75–80PubMedGoogle Scholar
  349. 11.
    Cocozza M, Picano T, Oliviero U, Russo N, Coto V, Nilani M (1995) Effects of picotamide, an antithromboxane agent, on carotid atherosclerotic evolution. A two-year, double-blind, placebo-controlled study in diabetic patients. Stroke 26:597–601PubMedCrossRefGoogle Scholar
  350. 12.
    Quarto di Palo F, Elli A, Rivolta R, Parenti M, Palazzi P, Zanussi C (1991) Prevention of chronic cyclosporine nephrotoxicity in renal transplantation by picotamide. Transplant Proc 23:969–971PubMedGoogle Scholar
  351. 1.
    Adams K, Allen JA, Brooker PC et al. (1994) Genotoxicity testing of pidotimod in vitro and in vivo. Arznf 44:1454–1459Google Scholar
  352. 2.
    d’Angelo L, De Ponti F, Crema F et al. (1994) Effect of food on the bioavailibility of pidotimod in healthy volunteers. Arznf 44:1473–1475Google Scholar
  353. 3.
    Benetti GP, Illeni MT, Passera A et al. (1994) Ex vivo evaluation of pidotimod activity in patients with chronic abstractive pulmonary disease. Arznf 44:1503–1505Google Scholar
  354. 4.
    Bisetti A, Ciappi G, Bariffi F et al. (1994) Evaluation of the efficacy of pidotimod in the exacerbations in patients affected with chronic bronchitis. Arznf 44:1499–1502Google Scholar
  355. 5.
    Burgio GR, Marseglia GL, Severi F et al. (1994) Imrnunoactivation by pidotimod in children with recurrent respiratory infections. Arznf 44:1525–1529Google Scholar
  356. 6.
    Ciaccia A (1994) Pidotimod activity against bronchitis exacerbations. Arznf 44:1516–1520Google Scholar
  357. 7.
    Clemente E, Solli R, Mei V et al. (1994) Therapeutic efficacy and safety of pidotimod in the treatment of urinary tract infections in children. Arznf 44:1490–1494Google Scholar
  358. 8.
    Coppi G, Amico-Roxas M, Berte F et al. (1994) Toxicological evaluation of pidotimod. Arznf 44:1448–1453Google Scholar
  359. 9.
    Di Renzo M, Pasqui AL, Bruni F et al. (1997) The in vitro effect of pidotimod on some immune functions in cancer patients. Immunopharmacol Immunotoxicol 19:37–51PubMedCrossRefGoogle Scholar
  360. 10.
    Mailland F, Coppi G, Silingardi S (1994) Pharmacokinetics and oral bioavailibility of pidotimid in humans. Arznf 44:1465–1469Google Scholar
  361. 11.
    Motta G, De Campora E, De Vita C et al. (1994) Immunoactivity of pidotimod against episodes of recurrent tonsillitis in childhood. Arznf 44:1521–1524Google Scholar
  362. 12.
    Spotti D, Biffi M, Coppi G et al. (1994) Pharmacokinetics of pidotimod in elderly volunteers and in renal failure patients. Arznf 44:1470–1472Google Scholar
  363. 1.
    Mailland F, Signorelli G, Coppi G (1991) Drugs Fut 16:1096–1098Google Scholar
  364. 2.
    Schröder E, Klieger E (1964) Liebigs Ann Chem 673:196–207CrossRefGoogle Scholar
  365. 3.
    Magni A, Signorelli G, Bocchiola G (1994) Arzneim-Forsch/Drug Res 44:1402–1404Google Scholar
  366. 4.
    Crimella T, Orlandi R, Bocchiola G et al. (1994) ArzneimForsch/Drug Res 44:1405–1410Google Scholar
  367. 1.
    Noack E, Cawello W, Bonn R (1987) Arzneim Forsch 37:407–409Google Scholar
  368. 2.
    Ventura P, Zanol M, Visconti M, Pifferi G (1978) J Chromatogr 161:237–242PubMedCrossRefGoogle Scholar
  369. 1.
    Elpern B, Carabateas P, Soria AE, Gardner LN et al. (1959) J Am Chem Soc 81:3784–3786CrossRefGoogle Scholar
  370. 2.
    Moffact AC (Hrsg.) (1986) Clarke’s Isolation and Identification of Drugs, 2. Aufl., The Pharmaceutical Press, London, S.903Google Scholar
  371. 3.
    Clarke ECG (1969) Isolation and Identification of Drugs, The Pharmaceutical Press, London, S.501Google Scholar
  372. 4.
    Jane I, McKinnon A, Flanagan RJ (1985) J Chromatogr 323:191–225PubMedCrossRefGoogle Scholar
  373. 5.
    Baker JK, Skelton RE, Ma CY (1979) J Chromatogr 168:417–427CrossRefGoogle Scholar
  374. 1.
    Kaariainen I, Ahtee L (1976) Effect of narcotic analgesic on the striatal homovanillic acid content in mice; relation to antinociceptirve effect. Med Biol 54:56–61PubMedGoogle Scholar
  375. 1.
    Mannhold R (1985) Drugs Fut 10:570–571Google Scholar
  376. 1.
    Fitton A, Brogden RN (1994) Pimobendan. A review of its pharmacology and therapeutic potential in congestive heart failure. Drugs Aging 4:417–441PubMedCrossRefGoogle Scholar
  377. 2.
    Holubarsch C (1997) New inotropic concepts: rationale for and differences between calcium sensitizers and phosphodiesterase inhibitors. Cardiology 88(Suppl 2): 12–20PubMedCrossRefGoogle Scholar
  378. 3.
    Mathew L, Katz SD (1998) Calcium sensititising agents in heart failure. Drugs Aging 12:191–204PubMedCrossRefGoogle Scholar
  379. 4.
    Nielen-Kudsk JE, Aldershvile J (1995) Will calcium sensitizers play a role in the treatment of heart failure? J Cardiovasc Pharmacol 26(Suppl 1):S77–S84Google Scholar
  380. 5.
    Haikala H, Linden IB (1995) Mechanisms of action of calcium-sensitizing drugs. J Cardiovasc Pharmacol 26(Suppl 1):S10–S19PubMedGoogle Scholar
  381. 6.
    Sata M, Sugiura S, Yamashita H, Aoyagi T, et al. (1995) Pimobendan directly sensitizes reconstituted thin filament to slide on cardiac myosin. Eur J Pharmacol 290:55–59PubMedCrossRefGoogle Scholar
  382. 7.
    Pagel PS, Hettrick DA, Wartlier DC (1996) Comparison of the effects of levosimendan, pimobendan, and milrinone on canine left ventricular-arterial coupling and mechanical efficiency. Basic Res Cardiol 91:296–307PubMedCrossRefGoogle Scholar
  383. 8.
    Fujimoto S (1994) Effects of pimobendan, its acitve metabolite UD-CG 212, and milrinone on isolated blood vessels. Eur J Pharmacol 265:159–166PubMedCrossRefGoogle Scholar
  384. 9.
    Remme WJ, Kruijssen DA, van Hoogenhuyze DC, Kraus XH, et al (1994) Hemodynamic, neurohumoral, and myocardial energetic effects of pimobendan, a novel calciumsensitizing compound, in patients with mild to moderate heart failure. J Cardiovasc Pharmacol 24:730–739PubMedCrossRefGoogle Scholar
  385. 10.
    Chen CH, Nakaya Y, Minami K, Kubo M (1997) Effects of pimobendan and its active metabolite, UD-CG 212 CL, on CA2+ activated K+ channels in vascular smooth-muscle cells. J Cardiovasc Pharmacol 30:739–743PubMedCrossRefGoogle Scholar
  386. 11.
    Hagemeijer F (1994) Hemdoynamic performance during exercise in patients with severe chronic congestive heart failure before and after a single dose of pimobendan. J Cardiovasc Pharmacol 23:741–746PubMedCrossRefGoogle Scholar
  387. 12.
    Lubsen J, Just H, Hjalmarsson AC, La Framboise D, et al. (1996) Effect of pimobendan on exercise capacity in patients with heart failure: main results from the pimobendan in congestive heart failure (PICO) trial. Heart 76:223–231PubMedCrossRefGoogle Scholar
  388. 13.
    Kato K (1997) Clinical efficacy and safety of pimobendan in treatment of heart failure — experience in Japan. Cardiology 88(Suppl 2):28–36PubMedCrossRefGoogle Scholar
  389. 14.
    Sasyama S, Asanoi H, Kihara Y, Yokawa S, et al. (1994) Clincal effects of longterm administration of pimobendan in patients with moderate congestive heart failure. Heart Vessels 9:113–120CrossRefGoogle Scholar
  390. 15.
    Remme WJ, Krayenbuhl HP, Baumann G, Frick MH, et al. (1994) Long-term efficacy and safety of pimobendan in moderate heart failure. A double-blind parallel 6-month comparison with enalapril. The Pimobendan-Enalapril Study Group. Eur Heart J 15:847–956CrossRefGoogle Scholar
  391. 16.
    Kubo SH (1997) Effect of pimobendan on exercise tolerance and quality of life in patients with heart failure. Cardiology 88(Suppl 2):21–27PubMedCrossRefGoogle Scholar
  392. 17.
    Dhu KM, Shieh SM, Hu OY (1995) Pharmacokinetics and pharmacodynamics of enantiomers of pimobendan in patients with dilated cardiomyopathy and congestive heart failure after single and repeated oral dosing. Clin Pharmacol Ther 57:610–621CrossRefGoogle Scholar
  393. 18.
    Chu KM, Shieh SM, Hu OY (1995) Plasma and red blood cell pharmacokinetics of pimobendan enantiomers in healthy Chinese. Eur J Clin Pharmacol 47:537–542PubMedCrossRefGoogle Scholar
  394. 19.
    Pahernik SA, Schmid J, Sauter T, Schildberg FW, et al. (1995) Metabolism of pimobendan in long-term human hepatocyte culture: in vivo-in vitro comparison. Xenobiotica 25:811–823PubMedCrossRefGoogle Scholar
  395. 1.
    Drugs Fut (1990) 15:761-762Google Scholar
  396. 2.
    Webb P, Threadgill MD (1990) J Label Compd Radiopharm 28:257–264CrossRefGoogle Scholar
  397. 3.
    Ward R. Workman P (1987) J Chromatogr 420:223–227PubMedCrossRefGoogle Scholar
  398. 4.
    Workman P, Twentyman PR (1982) Br J Cancer 46:249–259PubMedCrossRefGoogle Scholar
  399. 5.
    Smithen CE, Clarke ED, Dale JA et al. (1980) Radiation Sensitizers: Their Use in Clinical Management of Cancer 5:22–32Google Scholar
  400. 6.
    Malcom SL, Lee A, Groves JK et al. (1980) J Chromatogr 273:327–333Google Scholar
  401. 7.
    Williams MV, Denekamp J, Minchinton AI, Stratford MRL (1982) Br J Cancer 46:127–137PubMedCrossRefGoogle Scholar
  402. 8.
    Serradell MN, Castañer J, Hopkins SJ (1986) Drugs Fut 11:580–584Google Scholar
  403. 1.
    Azuma C, Raleigh JA, Thrall DE (1997) 148:35-42Google Scholar
  404. 2.
    Laurent F, Canal P, Soula G (1989) Int J Radiat Oncol Biol Phys 16:1101–1103PubMedCrossRefGoogle Scholar
  405. 1.
    Hopkins SJ (1981) Drugs Fut 6:149–151Google Scholar
  406. 2.
    Petersen HJ, Nielsen CK, Martelli EA (1978) J Med Chem 21:773–780PubMedCrossRefGoogle Scholar
  407. 1.
    Drugs Fut (1991) 15(11): 1081-1083Google Scholar
  408. 1.
    El Kebbi IM, Roser S, Pollet RJ (1994) Regulation of glucose transport by pioglitazone in cultured muscle cells. Metabolism 43:953–958PubMedCrossRefGoogle Scholar
  409. 2.
    Saha AK, Kurowski TG, Colca JR, Ruderman NB (1994) Lipid abnormalities in tissues of the KKAy mouse: effects of pioglitazone on malonyl-CoA and diacyglycerol. Am J Physiol 267:E95–E101PubMedGoogle Scholar
  410. 3.
    Kemnitz JW, Elson DF, Roecker EB, Baum ST, Bergman RN, Meglasson MD (1994) Pioglitazone increases insulin sensitivity, reduces blood glucose, insulin, and lipid levels, and lowers blood pressure, in obese, insulin-resistant rhesus monkeys. Diabetes 43:204–211PubMedCrossRefGoogle Scholar
  411. 4.
    Zhang HY, Reddy SR, Kotchen TA (1994) Antihypertensive effect of pioglitazone ist not invariably assiocated with increased insulin sensitivity. Hypertension 24:106–110PubMedCrossRefGoogle Scholar
  412. 1.
    FCC III = Food Chemicals Codex (1981) 3. Aufl., National Academy Press, Washington DCGoogle Scholar
  413. 2.
    Gunner SW (1969) J Chromatogr 40(1):85–89, zit. nach CA (1969) 70:109198sPubMedGoogle Scholar
  414. 3.
    Wylie PL (1987) TecLab 11(135), 115–128, zit. nach CA (1987) 107:120843bGoogle Scholar
  415. 1.
    Bhat BG, Chandrasekhara N (1987) Metabolic disposition of piperidine in the rat. Toxicol 44:99–106CrossRefGoogle Scholar
  416. 2.
    Dahl AR (1982) The inhibition of rat nasal cytochrome P-450-dependent mono-oxygenase by the essence heliotro-pin (piperonal). Drug Metab Dispos 10:553–554PubMedGoogle Scholar
  417. 3.
    Mar 31, 1440Google Scholar
  418. 4.
    Peock S, Monder JW (1993) Arena tests with piperonal, a new louse repellent. J R Soc Health 113:292–294PubMedCrossRefGoogle Scholar
  419. Mar 31, S. 1440Google Scholar
  420. 1.
    Cheng HC, Kariya T, Gleason EM, Dage RC (1985) Studies on the mechanism of the positive inotropic effect of piroximone in cat papillary muscle. J Cardiovasc Pharmacol 7:747–752PubMedCrossRefGoogle Scholar
  421. 2.
    Cottier C, Follath F, Kiowski W, Pfisterer M, et al. (1987) Acute hemodynamic effects of MDL 19205 in mild congestive heart failure. J Cardiovasc Pharmacol 9:209–212PubMedCrossRefGoogle Scholar
  422. 3.
    Axelrod RJ, De Marco T, Dae M, Botvinick EH, et al. (1987) Hemodynamic and clinical evaluation of piroximone, a new inotrope-vasodilator agent, in severe congestive heart failure. J Am Coll Cardiol 9:1124–1130PubMedCrossRefGoogle Scholar
  423. 4.
    Baumann PC, Meyer BJ, Maggiorini M, Ha HR, et al. (1993) Hemodynamic effects and concentration-effect relationship of a graded infusion of piroximone in patients with severe heart failure. J Cardiovasc Pharmacol 21:489–495PubMedCrossRefGoogle Scholar
  424. 5.
    Scholz M, Kneissl GD, Winkelmann BW, Grohe G, et al. (1995) Akute hämodynamische Effekte von Piroximon i.v. bei Patienten mit schwerer Herzinsuffizienz. Z Kardiol 84:827–833PubMedGoogle Scholar
  425. 6.
    Petein M, Levine TB, Cohn JN (1984) Hemodynamic effects of a new inotropic agent, piroximone (MDL 19205), in Patients with chronic heart failure. J Am Coll Cardiol 4:364–371PubMedCrossRefGoogle Scholar
  426. 7.
    Nemanich JW, Shurman AJ, Rossen JD, Kremser C, et al. (1987) Effects of longterm therapy with oral piroximone on resting hemodynamics, peak aerobic capacity, and the anaerobic threshold in patients with heart failure. J Cardiovasc Pharmacol 10:580–588PubMedCrossRefGoogle Scholar
  427. 8.
    Baumann G, Ningel K, Cremer G (1990) Longterm treatment with piroximone in patients with chronic heart failure. Int J Cardiol 29:195–294PubMedCrossRefGoogle Scholar
  428. 9.
    Nony P, Boissel JP, Lievre M, Leizorovciz A, et al. (1994) Evaluation of the effect of phosphodiesterase inhibitors on mortality in chronic heart failure patients. A meta-analysis. Eur J Clin Pharmacol 46:191–196PubMedCrossRefGoogle Scholar
  429. 10.
    Haegele KD, Belz GG, Meinicke TT, Schechter PJ (1986) Pharmacokinetics of piroximone (MDL 19205) in healthy volunteers. Eur J Clin Pharmacol 31:239–242PubMedCrossRefGoogle Scholar
  430. 11.
    Fauvel JP, Bernard N, Laville M, Pozet N, et al. (1995) Pharmacokinetics of piroximone after oral and intravenous administration to patients with renal insufficiency. Br J Clin Pharmacol 39:187–189PubMedCrossRefGoogle Scholar
  431. 12.
    Haegele KD, Hinze C, Joder-Ohlenbusch AM, Cremer G, et al (1991) Effects of a standardized meal on the pharmacokinetics of the new cardiotonic agent piroximone. Arzneimittelforsch 41:1225–1229PubMedGoogle Scholar
  432. 13.
    Chatterjee K, Wolfe CL, DeMarco T (1994) Nonglycoside inotropes in congestive heart failure. Are they beneficial or harmful? Cardiol Clin 12:63–72PubMedGoogle Scholar
  433. 1.
    Kujath E, Schoenafinger K, Brendel J (1995) Ger. Offen. DE 4,337,335; zit. nach CA 123:83373fGoogle Scholar
  434. 1.
    Mulsch A, Hecker M, Mordvintcev PI, Vanin AF, et al. (1993) Enzymic and nonenzymic release of NO accounts for the vasodilator activity of the metabolites of CAS 936, a novel long-acting sydnonimine derivative. Naunyn Schmiedebergs Arch Pharmacol 347:92–100PubMedCrossRefGoogle Scholar
  435. 2.
    Bohn H, Beyerle R, Martorana PA Schonafenger K (1991) CAS 936, a novel sydnonimine with direct vasodilating and nitric oxide-donating properties: effects on isolated blood vessels. J Cardiovasc Pharmacol 18:522–527PubMedCrossRefGoogle Scholar
  436. 3.
    Schini VB, Bond R, Gao Y, Illiano S, et al. (1993) The sydnonimine C 87-3754 evokes endothelium-independent relaxations and prevents endothelium-dependent contractions in blood vessels of the dog. J Cardiovasc Pharmacol 22(Suppl 7):S10–S16PubMedGoogle Scholar
  437. 4.
    Bohn H, Martorana PA, Schonafinger K (1992) Cardiovascular effects of the new nitric oxide donor, pirsidomine. Hemodynamic profile and tolerance studies in anesthetized and conscious dogs. Eur J Pharmacol 220:71–78PubMedCrossRefGoogle Scholar
  438. 5.
    Wainwright CL, Martorana PA (1993) Pirsidomine, a novel nitric oxide donor, suppresses ischemic arrhythmias in anesthetized pigs. J Cardiovasc Pharmacol 22(Suppl 7):S44–S50PubMedGoogle Scholar
  439. 6.
    Martorana PA, Kettenbach B, Bohn H, Schonafinger K, et al. (1994) Antiischemic effects of pirsidomine, a new nitric oxide donor. Eur J Pharmacol 257:267–273PubMedCrossRefGoogle Scholar
  440. 7.
    Bassenge E, Zanzinger J (1993) Effectiveness of an NO-releasing pirsidomine derivative on coronary conductance during long-term administration. J Cardiovasc Pharmacol 22(Suppl 7): S22–S26PubMedGoogle Scholar
  441. 8.
    Stengele E, Ruf G, Jahnchen E, Trenk D, et al. (1996) Short-term hemodynamic, anti-ischemic, and antianginal effects of pirsidomine, a new sydnonimine. Am J Cardiol 77:937–941PubMedCrossRefGoogle Scholar
  442. 1.
    Keller K, Greiner S, Stockebrand (1995) Horn. AM, Govi-Verlag, 6. Lieferang:Bd. 3Google Scholar
  443. 1.
    Keller K, Greiner S, Stockebrand (1995) Horn. AM, Govi-Verlag, 6. Lieferung: Bd. 3Google Scholar
  444. 2.
    DHU, Karlsruhe (1994) S. 238-239Google Scholar
  445. 3.
    Boericke W (1994) Horn. Mittel und ihre Wirkungen, Wissenschaftl. Autorenverlag Leer/Ostfriesland: S. 405Google Scholar
  446. 4.
    Voisin H (1969) Materia medica des hom. Praktikers, Haug-Verlag Heidelberg: S. 973–978Google Scholar
  447. 1.
    Gleason JG, Hall FH, Perchonock CD, Erhard KF, Frazee JS, Ku TW, Konrad K, McCarthy ME, Mong S, Crooke ST, Chi-Rosso G, Wasserman MA, Torphy TJ, Muccitelli RM, Hay DW, Tucker SS, Vickery-Clark L (1987) J Med Chem 30:959–961PubMedCrossRefGoogle Scholar
  448. 2.
    Flisak JR, Gombatz KJ, Holmes MM, Jarmas AA, Lantos I, Mendelson WL, Novack VJ, Remich JJ, Snyder L (1993) J Org Chem 58:6247–6254CrossRefGoogle Scholar
  449. 1.
    Chanarin N, Johnston SL (1994) Leukotrienes in asthma. Drugs 47:12–24PubMedCrossRefGoogle Scholar
  450. 2.
    Hay DW, Muccitelli RM, Vickery-Clark LM, Novak LS, Osborn RR, Gleason JG, Yodis LA, Saverion CM, Eckardt RD, Sarau HM, et al. (1991) Pharmacological and pharmacokinetic profile of SK&F S-106203, a potent, orally active peptidoleukotriene receptor antagonist, in guinea pig. Pulm Pharmacol 4:177–189PubMedCrossRefGoogle Scholar
  451. 3.
    Wassermann MA, Torphy TJ, Hay DW, Muccitelli RM, Tucker SS, Wilson KA, Osborn RR, Vickery-Clark L, Hall RF, Erhard KF (1987) Pharmacologic profile of SK&F 104353, a novel, highly potent and selective peptidoleukotriene antagonist. Adv Prostagland Thrombo-xane Leukot Res 17A:532–535Google Scholar
  452. 4.
    Hay DW, Muccitelli RM, Tucker SS, Vickery Clark LM, Wilson KA, Gleason JG, Hall RF, Wasserman MA, Torphy TJ (1987) Pharmacologic profile of SK&F 104353: a novel, potent and selective peptidoleukotriene receptor antagonist in guinea pig and human airways. J Pharmacol Exp Ther 243:474–481PubMedGoogle Scholar
  453. 5.
    Cook JA, Li EJ, Spicer KM, Wise MC, Halushka PV (1990) Effect of leukotriene receptor antagonists on vascular permeability during endotoxic shock. Circ Shock 32:209–218PubMedGoogle Scholar
  454. 6.
    Zellner JL, Cook JA, Reines DH, Wise WC, Smith EF, Kessler LD, Halushka PV (1990) Hemodynamic effects of leukotriene LTD4 and a LTD4 receptor antagonist in the pig. Eicosanoids 3:219–224PubMedGoogle Scholar
  455. 7.
    Spencer DA, Evans JM, Green SE, Piper PJ, Costello JF (1991) Participation of the cysteinyl leukotrienes in the acute bronchoconstrictor response to inhaled platelet activating factor in man. Thorax 46:441–445PubMedCrossRefGoogle Scholar
  456. 8.
    Christie PE, Smith CM, Lee TH (1991) The potent and selective sulfidopeptide leukotriene antagonists, SK&F 104353, inhibits aspirin-induced asthma. Am Rev Respir Dis 144:957–958PubMedCrossRefGoogle Scholar
  457. 9.
    Joos GF, Kips JC, Pauwels RA, Van der Straeten ME (1991) The effect of aerosolized SK&F 104353-Z2 on the bronchoconstrictor effect of leukotriene D4 in asthmatics. Pulm Pharmacol 4:37–42PubMedCrossRefGoogle Scholar
  458. 10.
    Robuschi M, Riva E, Fuccella LM, Vida E, Barnabe R, Rossi M, Gambaro G, Spagnotto S, Bianco S (1992) Prevention of exercise-induced bronchoconstriction by a new leukotriene antagonist (SK&F 104353). A double-blind study versus disodium cromoglycate and placebo. Am Rev Respir Dis 145:1285–1288PubMedCrossRefGoogle Scholar
  459. 11.
    Kroegel C, Herzog V, Knöchel B, Julius P, Luttmann W, Virchow Jr JC (1996) 5-Lipoxigenase-Inhibitoren und Leukotrien-Rezeptorantagonisten. Pathophysiologische Grundlagen und klinische Anwendung. Arzneimitteltherapie 14:299–309Google Scholar
  460. 1.
    Förster M, Vahrenkamp H (1995) Chem Ber 128:541–550CrossRefGoogle Scholar
  461. 1.
    Seiki M, Ueki S, Tanaka Y, Soeda M, Hori Y, Aita H, Yoneta T, Morita H, Tagashira E, Okabe S (1990) Folia Pharmacol Jpn 95:257–269CrossRefGoogle Scholar
  462. 2.
    Pfeiffer CJ, Cho CH, Cheema A, Saltman D (1989) Eur J Pharmacol 61:347–353CrossRefGoogle Scholar
  463. 3.
    Cho CH, Ogle CW, Dai S (1976) Eur J Pharmacol 38:337–341PubMedCrossRefGoogle Scholar
  464. 1.
    Noa M, Herrera M, Magraner J, Más R (1994) J Pharm Pharmacol 46:282–285PubMedCrossRefGoogle Scholar
  465. 2.
    Informationen der PZ (1996) Pharm Ztg 33:88Google Scholar
  466. 1.
    Rodriguez-Echenique C, Mesa R, Mas R, Noa M, Menendez R, Gonzalez RM, Amor AM, Fraga V, Sotolongo V, Laguna A (1994) Effects of policosanol chronically administered in male monkeys (Macaca arctoides). Food Chem Toxicol 32:565–575PubMedCrossRefGoogle Scholar
  467. 2.
    Mesa AR, Mas R, Noa M, Hernandez C, Rodeiro I, Gamez R, Garcia M, Capote A, Aleman CL (1994) Toxicity of policosanol in beagle dogs: one-year study. Toxicol Lett 73:81–90PubMedCrossRefGoogle Scholar
  468. 3.
    Arruzazabala ML, Carbajal D, Mas R, Garcia M, Fraga V (1993) Effects of polisosanol on platelet aggregation in rats. Thromb Res 69:321–327PubMedCrossRefGoogle Scholar
  469. 4.
    Carbajal D, Arruzazabala ML, Mas R, Molina V, Valdes S (1994) Effect of policosanol on experimental thrombosis models. Prostaglandins Leukotr Essent Fatty Acids 50:249–251CrossRefGoogle Scholar
  470. 5.
    Arruzazabala ML, Molina V, Carbajal D, Valdes S, Mas R (1993) Effect of połicosanol on cerebral ischemia in Mongolian gerbils: role of prostacyclin and thromboxane A2. Prostaglandins Leukotr Essent Fatty Acids 49:695–697CrossRefGoogle Scholar
  471. 6.
    Torres O, Agramonte AJ, Illnait J, Mas-Ferreiro R, Fernandez L, Fernandez JC (1995) Treatment of hypercholesterolemia in NIDDM with policosanol. Diabetes Care 18:393–397PubMedCrossRefGoogle Scholar
  472. 7.
    Batista J, Stusser R, Saez F, Perez B (1996) Effect of policosanol on hyperlipidemia and coronary heart disease in middle-aged patients. A 14-month pilot study. Int Clin Pharmacol Ther 34:134–137Google Scholar
  473. 1.
    Pharmeuropa (1992) 4(3): 188-190Google Scholar
  474. 1.
    Pharmeuropa (1992) 4:189-192Google Scholar
  475. 1.
    Pharmeuropa (1993) 5(1):20-21Google Scholar
  476. 1.
    Pharmeuropa (1994) 6:130-131Google Scholar
  477. 1.
    Pharmeuropa (1996) 8(3):380-382Google Scholar
  478. 1.
    Pharmeuropa (1994) 6:6Google Scholar
  479. 1.
    Sundkvist G, Armstrong FM, Bradbury JE, Chaplin C, Ellis SH, Owens DR, Rosen I, Sonksen P (1992) Peripheral and autonomic nerve function in 259 diabetic patients with peripheral neuropathy treated with ponalrestat (an aldose reductase inhibitor) or placebo for 18 months. United Kingdom/Scandinavian Ponalrestat Trial. J. Diabet Complications 6:123–130CrossRefGoogle Scholar
  480. 2.
    Ziegler D, Mayer P, Rathmann W, Gries FA (1991) Oneyear treatment with the aldose reductase inhibitor, ponalrestat, in diabetic neuropathy. Diabetes Res Clin Pract 14:63–73PubMedCrossRefGoogle Scholar
  481. 3.
    Pedersen MM, Christiansen JS, Mogensen CE (1991) Reduction of glomerular hyperfiltration in normalbuminuric IDDM patients bei 6 month of aldose reductase inhibition. Diabetes 40:527–531PubMedCrossRefGoogle Scholar
  482. 1.
    Schneider CS, Mierau J (1987) J Med Chem 30:494–498PubMedCrossRefGoogle Scholar
  483. 2.
    Griss G, Schneider C, Hurnaus R, Krobinger W, Bauer R, Mierau J (Dr. Karl Thomae GmbH)AU 8551544, DE 3447075, DE 3508947, EP 186087, ES 8707513, ES 8707514, ES 8707515, JP 86155377, US 4731374; zit. nach de Angelis L (1992) Drugs Fut 17:291-292Google Scholar
  484. 3.
    Produktinformation, Boehringer Ingelheim KG, 55216 IngelheimGoogle Scholar
  485. 1.
    Oberdisse E, Hackenthal E, Kuschinski K (Hrsg.) (1997) Pharmakologie und Toxikologie, Springer-Verlag, Berlin HeidelbergGoogle Scholar
  486. 2.
    Baas H, Deuschl G, Oertel W, Poewe W (1997) Deutsch Apoth Ztg, 137:264–270Google Scholar
  487. 3.
    Seeman P, Van Tol HM (1994) Trends Pharmacol Sci 15:264–270PubMedCrossRefGoogle Scholar
  488. 4.
    Hagan JJ, Middlemiss DN, Sharpe PC, Poste GH (1997) Trends Pharmacol Sci 18:156–163PubMedGoogle Scholar
  489. 5.
    Parkinson Study Group (1997) J Am Med Ass 278:125–130CrossRefGoogle Scholar
  490. 1.
    L’Italien YJ, Nordin IC; Belg 864,269; Brit 1,588,082; Can 1,073,457; Fr 2,382,441; Ger Offen 2,808,067; Jpn K 78,108,966; Span 467,288; US 4,145,347 (1983) Drugs Fut 8(9):795-796Google Scholar
  491. 1.
    Auteri A, Biardi P, Celasco G, et al (1992) Pharmacokinetics of pramiracetam in healthy volunteers after oral administration (1992): Int J Clin Pharmacol Res 12:129–132PubMedGoogle Scholar
  492. 2.
    Brust P (1989) Reversal of scopolamine-induced alterations of choline transport across the blood-brain barrier by the nootropics piracetam and pramiracetam. Arzneimittelf. 39:1220–1222Google Scholar
  493. 3.
    Butler DE, Nordin IC, L’Italien YJ, et al (1984) Amnesiareversal activity of a series of N-(disubstituted amino)alkyl)-2-oxo-l-pyrrolidineacetamides, including pramiracetam. J Med Chem 27:684–691PubMedCrossRefGoogle Scholar
  494. 4.
    Chang T, Young RM, Goulet JR, et al. (1985) Pharmacokinetics of oral pramiracetam in normal volunteers. J Clin Pharmacol 25:291–295PubMedCrossRefGoogle Scholar
  495. 5.
    Claus JJ, Ludwig C, Mohr E, et al. (1991) Nootropic drugs in Alzheimer’s disease: symptomatic treatment with pramiracetam. Neurol 41:570–574CrossRefGoogle Scholar
  496. 6.
    Gouliaev AH, Senning A (1994) Piracetam and other structurally related nootropics. Brain Res Rev 19:180–222PubMedCrossRefGoogle Scholar
  497. 7.
    Hlinak Z, Krejci (1995) Kynurenic acid and 5,7-dichlorokynurenic acids improve social and object recognition in male rats. Psychopharmacol 120:463–469CrossRefGoogle Scholar
  498. 8.
    McLean A, Cardenas DD, Burgess D, et al. (1991) Placebo-controlled study of pramiracetam in young males with memory and cognitive problems resulting from head injury and anoxia. Brain Inj 5:375–380PubMedCrossRefGoogle Scholar
  499. 9.
    Poschel BP, Ho PM, Nintemann FW (1985) Arousal deficit shown in aged rat’s quantitative EEG and ameliorative action of pramiracetam compared to piracetam. Experientia 41:1433–1435PubMedCrossRefGoogle Scholar
  500. 10.
    Pugsley TA, Shih YH, Coughenour L, et al. (1983) Some neurochemical properties of pramiracetam (CI-879), a new cognition-enhancing agent. Drug Devel Res 3:407–420CrossRefGoogle Scholar
  501. 1.
    Ritchie JM, Greene NM (1985) Local anesthetics. In: Gilman EG, Goodman LS, Rall TW, Murad F (Hrsg.) Goodman and Gilman’s The pharmacological basis of therapeutics, 7. Aufl., MacMillan Publishing Comp, New York Toronto London, S. 302 ffGoogle Scholar
  502. 2.
    Schmidt JL, Blockus LE, Richards RK (1953) Anesth Analg 32:418–424CrossRefGoogle Scholar
  503. 3.
    Peal L, Karp M (1954) Anesthesiology 15:637–643PubMedCrossRefGoogle Scholar
  504. 4.
    Sladek WR (1970) AJCR 1:33–40Google Scholar
  505. 5.
    van Ketel WG (1981) Contact Dermatitis 7:49CrossRefGoogle Scholar
  506. 1.
    Drug Fut (1988) 13:317-320Google Scholar
  507. 2.
    Nakai H, Konno S, Sauyama S, Toda M, Arai Y, Obata T, Katsube N, MiyamotoT, Okegawa T, Kawasaki A (1988) J Med Chem 31:84–91PubMedCrossRefGoogle Scholar
  508. 1.
    Nabe T, Kohno S, Tanpo T, Saeki Y, Yamamura H, Horiba M, Ohata K (1994) Prostagland Leuk Essent Fatty Acids 51:163–169CrossRefGoogle Scholar
  509. 2.
    Nakai H, Konno M, Kosuge, Sakuyama S, Toda M, Arai Y, Obata T, Katsube N, Miyuamoto R, Okegawa T, Kawasaki A (1988) J Med Chem 31:84–91PubMedCrossRefGoogle Scholar
  510. 3.
    Nakagawa N, Obata T, Kobayashi T, Okada Y, Nambu F, Terawaki T, Furuya T, Muryobayashi K, Sawada M, Aishita H (1993) Eur J Pharmacol 235:211–221PubMedCrossRefGoogle Scholar
  511. 4.
    Abraham WM, Ahmed A, Cortes A, Sielczak M, Hallmon J (1993) Prostagland Leuk Essent Fatty Acids 48:233–240CrossRefGoogle Scholar
  512. 5.
    Nakagawa N, Obata T, Kobayashi T, Okada Y, Terawaki T, Aishita H (1992) Jpn J Pharmacol 60:217–225PubMedCrossRefGoogle Scholar
  513. 6.
    Taniguchi Y, Tamura G, Honma M, Aizawa T, Maruyama N, Shirato K, Takishima T (1993) J Allergy Clin Immunol 92:507–512PubMedCrossRefGoogle Scholar
  514. 7.
    Yamamoto H, Nagata M, Kuramitus K, Tabe K, Kiuchi H, Sakamoto Y, Yamamoto K, Dohi Y (1994) Am J Resp Crit Care Med 150:254–257PubMedCrossRefGoogle Scholar
  515. 8.
    Taki F, Suzuki R, Torii K, Matsumoto S, Taniguchi H, Takagi K (1994) Arzneim-Forsch/Drug Res 44:330–338Google Scholar
  516. 9.
    Kikucchi K, Makiyama K, Okazaki K (1993) Clin Rep 27:259–264Google Scholar
  517. 10.
    Yonezawa H, Akimoto A, Fujita T (1992) Pharmacometrics 44:197–205Google Scholar
  518. 11.
    Mitsuzono T, Isowa H, Kashima H, Aoyama N, Ueda T, Takada M, Tamya I, Matsuoka Y, Fujita T (1992) Pharmacometrics 44:205–212Google Scholar
  519. 1.
    Walker GN (Ciba-Geigy AG) EP 143,142 (1987) Drugs Fut 12(8):773-774Google Scholar
  520. 1.
    Cavalla JF, Jones R, Welford M, Wax J et al. (1964) J Med Chem 7:412–415PubMedCrossRefGoogle Scholar
  521. 2.
    Lockhart IM, Webb NE (1970) Chem Ind (London) 1230Google Scholar
  522. 3.
    Clarke ECG (1975) Isolation and Identification of Drugs, 2. Aufl., The Pharmaceuticale Press, London, S. 1088Google Scholar
  523. 4.
    Musumarra G, Scarlata G, Romano G, Clementi S et al. (1984) J Chromatogr Sci 22:538–547CrossRefGoogle Scholar
  524. 1.
    Young AM, Stephens KR, Hein DW, Woods JH (1984) Reinforcing and discriminative stimulus properties of mixed agonist-antagonist opioids. J Pharmacol Exp Ther 229:118–126PubMedGoogle Scholar
  525. 1.
    Naseem J, Ahmad M, Hadi SM (1988) Biosci Rep 8:485–92PubMedCrossRefGoogle Scholar
  526. 2.
    Mar 31, S. 1114Google Scholar
  527. 1.
    Li CH, Dixon JS, Lo TB, Pankov YA, Schmidt KD (1969) Nature 224:695–696CrossRefGoogle Scholar
  528. 2.
    Reisfeld RA, Tong GL, Rickes EL, Brink NG, Steelman SL (1961) J Am Chem Soc 83:3717–3719CrossRefGoogle Scholar
  529. 3.
    Voss HE (1954) Arzneim Forsch 4:467–477Google Scholar
  530. 1.
    Nagy E, Berci I, Friesen HG (1983) Regulation of immunity in rats by lactogenic and growth hormones, Acta Endocrinol 102:351–357PubMedGoogle Scholar
  531. 1.
    Seeger E, Kottier A (Dr. Karl Thomae GmbH, 1.12.1960) DBP 1093799, zit. nach CA (1961) 55:19950cGoogle Scholar
  532. 2.
    Dr. Karl Thomae GmbH (21.1.1959) BP 897835, zit. nach CA(1959) 53:12306iGoogle Scholar
  533. 3.
    Rücker G, Neugebauer M, Zhong D (1992) Arch Pharm 325:47–52CrossRefGoogle Scholar
  534. 4.
    Dissertation Dafang Zhong (1989) Universität BonnGoogle Scholar
  535. 5.
    Moffat AC (Hrsg.) (1986) Clarke’s Isolation and Identification of Drugs, 2. Aufl., The Pharmaceutical Press, LondonGoogle Scholar
  536. 6.
    Daldrup T, Susanto F, Michalke P (1981) Fresenius’ Z Anal Chem 308(5):413–427CrossRefGoogle Scholar
  537. 7.
    Rücker G, Neugebauer M, Zhong D (1992) Xenobiotica 22(2):143–152PubMedCrossRefGoogle Scholar
  538. 1.
    Piquet V, Desmeules JA, Collart L, Dayer P (1994) Quelle posologie antalgique du paracetamol? Schweiz Med Wochenschr 124:2196–2198Google Scholar
  539. 2.
    Depre M, van Hecken A, Verbesselt R, Tjandra-Maga TB, Gerin M, de Schepper PJ (1992) Tolerance and pharmacokinetics of propacetamol, a paracetamol formulation for intravenous use. Fundamental Clin Pharmacol 8:259–262CrossRefGoogle Scholar
  540. 3.
    Farhat F, Savoyen MC, Jayr C (1995) Efficacité du propacetamol sur la douleur postopératoire selon deux modes d’administration intraveineuse. Cahiers d’anaesthesiol 43:351–356Google Scholar
  541. 4.
    Delbos A, Boccard E (1995) The morphine-sparing effect of propacetamol in orthopedic postoperative pain. J Pain Symptom Managern 10:279–286CrossRefGoogle Scholar
  542. 5.
    Monrigal C, Jacob JP, Grany JC (1994) Comparison de l’efficacité analgesique de la nalbuphine et de son association au propacetamol en phase postoperatoire immediate de chirurgie gyneceo-obsteticale. Ann Franc Anesth Reanima 13:153–157CrossRefGoogle Scholar
  543. 6.
    Hans P, Brichant JF, Bonhomme V, Triffaux M (1993) Analgesic efficiency of propacetamol hydrochloride after lumbar disc surgery. Acta Anesthesiol Belgica 44:129–133Google Scholar
  544. 7.
    Autret E, Duterte JP, Breteau M, Furet Y, Laugier J (1993) Pharmacokinetics of paracetamol in the neonate and infant after administration of propacetamol chlorhydrate. Developmental Pharmacol Therap 20:129–134Google Scholar
  545. 1.
  546. 2.
    Ishiwata Y, Suzuki E, Yokochi S, Otsuka T, Tasaka F, Usuda H, Mitani T (1994) Studies on the antiviral activity of propagermanium with immunostimulating action. Arzneimittelforsch 44:357–361PubMedGoogle Scholar
  547. 3.
    Ishiwata Y, Yokochi S, Suzuki E, Michishita H, Tashita A, Asano K, Mitani T, Kurono M (1990) Effects of proxigermanium on interferon production and 2′,5′-oligoadenylate synthetase activity in the lung of influenza virus-infected mice and in virus-infected human peripheral blood mononuclear cell cultures. Arzneimittelforsch 40:896–899PubMedGoogle Scholar
  548. 1.
    Hiltmann R, Wollenweber H, Hoffmeister, Wirt W (1962) Bayer AG DBP 1134 981, zit. nach CA (1963) 58:4480gGoogle Scholar
  549. 1.
    Howells TH, Harnik E, Kellner GA, Rosenoer VM (1967) Propanidid and methohexitone: their comparative potency and narcotic action. Br J Anaesthesia 39:31–34CrossRefGoogle Scholar
  550. 2.
    Mar 31, S. 1261-1263Google Scholar
  551. 1.
    Bergel F, Morrison AL, Rinderknecht H (1944) J Chem Soc 265-267Google Scholar
  552. 2.
    Clarke ECG (1969) Isolation and Identification of Drugs, The Pharmaceutical Press, London, S. 520Google Scholar
  553. 3.
    Musumarra G, Scarlata G, Romano G, Clementi S et al. (1984) J Chromatogr Sci 22:538–547CrossRefGoogle Scholar
  554. 4.
    Jane I, McKinnon A, Flanagan RJ (1985) J Chromatogr 323:191–225PubMedCrossRefGoogle Scholar
  555. 5.
    Berdiev NB, Adamchuk LV, Rudko LS (1985) Zdravookhr Tadzh 70-71, zit. nach CA (1985) 103:158623kGoogle Scholar
  556. 1.
    Fearon DT, Austen KF (1975) Properdin: initiation of alternative complement pathway. Proc Natl Acad Sci USA 72:3220–3224PubMedCrossRefGoogle Scholar
  557. 1.
    Strack E, Müller DM (1970) Hoppe-Seyler’s Z Physiol Chem 351(l):95–98PubMedCrossRefGoogle Scholar
  558. 2.
    Strack E, Lorenz I (1966) Hoppe-Selyer’s Z Physiol Chem 343(4–6):231–239CrossRefGoogle Scholar
  559. 3.
    Malik S, Pratum TK, Ullah MS, Ahmad S, Kenny MA (1992) Can J Appl Spectrosc 37(6):157–160Google Scholar
  560. 1.
    Negwer M (1994) Organic-chemical Drugs and their Synonyms, Akademie-Verlag, Berlin, S. 2140Google Scholar
  561. 1.
    Scholz A, Richter G (1977) Zur Allergie gegen Falicain (Propipocainhydrochlorid). Dermatolog. Monatsschrift 163:966–969Google Scholar
  562. 2.
    Hallmann B, Rehmann O, Bormann B (1988) Lebensbedrohliche allergische Reaktionen durch Einsatz von Urocomb-Gel. Z Urol Nephrol 81:715–717PubMedGoogle Scholar
  563. 1.
    Göber B, Dressler K, Franke P, Alder L (1986) Pharmazie 41:840–842PubMedGoogle Scholar
  564. 2.
    Haruno A (1992) Arzneim Forsch 42:1459–1461Google Scholar
  565. 1.
    Haruno A (1992) Effects of propiverine hydrochloride on the spontaneous contractions of isolated guinea-pig urinary bladder strip and rhythmic urinary bladder contractions of anesthetized dog. Arzneimittelforsch 42:1459–1461PubMedGoogle Scholar
  566. 2.
    Wada Y, Yoshida M, Kitani K, Kikukawa H, et al. (1995) Comparison of the effects of various anticholinergic drugs on human isolated urinary bladder. Arch Int Pharmacodyn Ther 330:76–89PubMedGoogle Scholar
  567. 3.
    Riotte J, Mutschler E (1987) Untersuchungen zur spasmolytischen Aktivität von Propiverin und einigen seiner Strukturanaloga. Arzneimittelforsch 37:300–302PubMedGoogle Scholar
  568. 4.
    Wehnert J, Sage S (1989) Vergleichende Untersuchungen zur Wirkung von Mictonorm (Propiverin hydrochlorid) und Spasuret (Flavoxat hydrochlorid) auf den Detrusor vesicae. Z Urol Nephrol 82:259–263PubMedGoogle Scholar
  569. 5.
    Mazur D, Wehnert J, Dorschner W, Schubert G, et al. (1995) Clinical and urodynamic effects of propiverine in patients suffering from urgency and urge incontinence. A multicentre dose-optimizing study. Scand J Urol Nephrol 29:289–294PubMedCrossRefGoogle Scholar
  570. 6.
    Otto-Unger G (1985) Zur Behandlung der instabilen Blase des Kindes mit dem Anticholinergikum Propiverinhydrochlorid (Mictonorm/Mictonetten). Z Urol Nephrol 78:145–152PubMedGoogle Scholar
  571. 7.
    Hofner K, Dorschner W, Hofner T, Dietrich F (1986) Zur Wirkung von Mictonorm (Propiverinhydrochrolid) auf die weibliche Urethra. Zentralbl Gynäkol 108:1124–1129PubMedGoogle Scholar
  572. 8.
    Hausetin KO, Huiler G (1988) On the pharmacokinetics and metabolism of propiverine in man. Eur J Drug Metab Pharmacokinet 13:81–90CrossRefGoogle Scholar
  573. 9.
    Huiler G, Haustein KO, Scheithauer S (1988) Studies on the metabolic pattern of propiverine in urine after single administration. Pharmazie 43:91–95Google Scholar
  574. 10.
    Yarker YE, Goa KL, Fitton A (1995) Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging 6:243–262PubMedCrossRefGoogle Scholar
  575. 1.
    Hoffmann C, Faure A (1966) Bull Soc Chim Fr 7:2316–2319Google Scholar
  576. 2.
    Ozden I, Brachet-Liermain A; Bertucat M (1975) Ankara Univ Eczacilik Fac Mecm 5:68–81; zit. nach CA (1976) 85:182486yGoogle Scholar
  577. 3.
    Alary J, Villet A, Cœur A (1976) Ann Pharm Franc 34:419–426PubMedGoogle Scholar
  578. 4.
    Alary J, Villet A (1980) J Pharm Belg 35:408–416Google Scholar
  579. 5.
    Alary J, Villet A, Cœur A (1980) Talanta 27:659–663; zit. nach CA (1980) 93:245605zPubMedCrossRefGoogle Scholar
  580. 6.
    UPSA Laboratories, ProduktinformationGoogle Scholar
  581. 1.
    Mar 30, S. 1017Google Scholar
  582. 1.
    Dohm M, Diedrich P (1932) Liebigs Ann Chem 494:284–302CrossRefGoogle Scholar
  583. 2.
    GB 517382, zit. nach CA (1941) 35:7124Google Scholar
  584. 3.
    Moffat AC (Hrsg.) (1986) Clarke’s Isolation and Identification of Drugs, The Pharmaceutical Press, London, S.939Google Scholar
  585. 4.
    Hansch C, Sammes PG, Taylor JB (Hrsg.) (1990) Comprehensive Medicinal Chemistry, Pergamon Press, Oxford, Bd. 6, S.811Google Scholar
  586. 5.
    Elks J, Ganellin CR (Hrsg.) (1990) Dictionary of Drugs, Chapman and Hall, London, Nr. D-00363Google Scholar
  587. 6.
    Heinisch G, Matous H, Rank W, Wunderlich R (1981) Sci Pharm 49:472–482Google Scholar
  588. 7.
    Egli RA, Tanner S (1979) Fresenius’ Z Anal Chem 295:398–401CrossRefGoogle Scholar
  589. 1.
    Wardman AG, Willey RF, Cooke NJ, Crompton GK, Grant IW (1983) Unusual pulmonary reactions to oily propyliodone (Dionosil) in bronchography. Department of Respiratory Medicine, General Infirmary, Leeds. Br J Dis Chest 77, 1:98–103PubMedCrossRefGoogle Scholar
  590. 2.
    Willson JKV, Perilla FR, Hanchett RB (1956) Bronchography with dionosil (propyliodone), new adsorbable bronchographic medium. Am J Roentgenol 75, April:720–727Google Scholar
  591. 3.
    Tomich EG, Basil B, Davis B (1953) The properties of N-propyl-3,5-diiodo-4-pyridone-N-acetate (propyliodone). Brit J Pharmacol 8:166–170PubMedGoogle Scholar
  592. 1.
    Nakano J, Nishimura H (1971) Chem Pharm Bull 19:705–713, zit. nach CA (1972) 76:3791pCrossRefGoogle Scholar
  593. 2.
    Yurugi S, Kawasaki H, Noguchi S (1955) J Pharm Soc Japan 75:498–501, zit. nach CA (1956) 50:5679aGoogle Scholar
  594. 3.
    Chuang HP, Chiang HC, Wang KT (1969) J Chromatogr 41:487–488PubMedGoogle Scholar
  595. 1.
    Mar31, S. 1382Google Scholar
  596. 1.
    CA (1975) 22: 133011zGoogle Scholar
  597. 1.
    Clark’s Isolation an Identifiaction of Drugs, 2. Aufl., The Pharmaceutical Press, London (1986) S. 946Google Scholar
  598. 2.
    Hofmann A, Heim R, Brack A, Kobel H et al. (1959) Helv Chim Acta (XLII) 167-168:1557–1572CrossRefGoogle Scholar
  599. 1.
    Pratt SE, Brauer MA, Corwin MR (1981) Relative efficacies of pyrantel tartrate and pyrantel citrate against Oesophagostomum sp. in swine. Am J Vet Res 42:871–872PubMedGoogle Scholar
  600. 2.
    Alfredsen SA (1984) The treatment of gastro-intestinal worms in pigs. Norsk Veterinaertidsskrift 96:231–233Google Scholar
  601. 3.
    Conway DP, Raynaud JP (1978) Ascariasis in pigs and new chemoprophylactic agents. Proceedings of the 5th World International Pig Veterinary Society Congress, Zagreb, June 13–15Google Scholar
  602. 4.
    Robinson M (1979) Efficacy of oxantel tartrate against Trichuris suis in swine. Vet Parasitol 5:223–235CrossRefGoogle Scholar
  603. 5.
    Danek J, Sevcik B (1972) Efficiency of various pyrantel salts in a critical test sheep. Veterinaria, Spofa 14:91–102Google Scholar
  604. 6.
    Bjoern H, Roepstorff A, Nansen P, Waller PJ (1989) A dose-response investigation on the level of resistance to pyrantel citrate in nodular worms of pigs. Vet Parasitol 31:259–267CrossRefGoogle Scholar
  605. 1.
    Debarge A (1961) FR M828, zit. nach CA (1963) 58:9098gGoogle Scholar
  606. 1.
    Mar 31, S. 1656Google Scholar
  607. 1.
    US Pat. 31010966, zit. nach CA (1962) 56:13022FGoogle Scholar
  608. 2.
    Beu L, Faracasanu I, Russu O, Breazu et al. (1985) Revista de Chimie 36:496–499Google Scholar
  609. 3.
    Datenblatt der Firma E. Merck, DarmstadtGoogle Scholar
  610. 1.
    Cooper AJ, Magnus RV (1980) A placebo-controlled study of pyritinol („Encephabol“) in dementia. Pharmatherapeutica 2:317–322PubMedGoogle Scholar
  611. 2.
    Crouzet J, Beraneck L (1986) Pyrithioxin and rheumatoid polyarthritis. Rev Rhum Mal Osteoartic 53:45–48PubMedGoogle Scholar
  612. 3.
    Dayrens P, Ivanoff B, Cussac M, et al. (1983) Antiinflammatory and immunostimulant activities of six sulphur compounds — four benzenesulphonates, levamisole, and pyritinol hydrochloride — assayed in mouse cell activation studies. Arzneimittelf 33:372–377Google Scholar
  613. 4.
    Greiner HE, Haase AF, Seyfried CA (1988) Neurochemical studies on the mechanism of action of pyritinol. Pharmacopsychiatry 21 Suppl 1:26–32PubMedCrossRefGoogle Scholar
  614. 5.
    Hartmann H, Cohen SA, Muller WE (1993) Effects of sub-chronic administration of pyritinol on receptor deficits and phosphatidylinositol metabolism in the brain of the aged mouse. Neuropharmacol 32:119–125CrossRefGoogle Scholar
  615. 6.
    Hindmarch I, Coleston DM, Kerr JS (1990) Psychopharmacological effects of pyritinol in normal volunteers. Neuropsychobiol 24:159–164CrossRefGoogle Scholar
  616. 7.
    Jaiswal AK, Upadhyay SN, Bhattacharya SK (1990) Effect of pyritinol, a cerebral protector, on learning and memory deficits induced by prenatal undernutrition and environmental impoverishment in young rats. Indian J Exp Biol 28:609–615PubMedGoogle Scholar
  617. 8.
    Kitao K, Yata N, Kubo K, et al (1977) Biopharmaceutical study of pyrithioxin following oral and intravenous administration to dog. Chem Pharm Bull 25:1343–1349PubMedCrossRefGoogle Scholar
  618. 9.
    Kriegelstein J, Heuer H (1986) Die Nützlichkeit eines Modells akuter Hypoxie für die Testung der zerebroprotektive Arzneimittel. Arzneimittelf 36:1568–1571Google Scholar
  619. 10.
    Lemmel EM (1993) Comparison of pyritinol and auranofin in the treatment of rheumatoid arthritis. The European Multicentre Study Group. Brit J Rheumatol 32:375–382CrossRefGoogle Scholar
  620. 11.
    Martin KJ, Tucker L, Widdowson L (1988) Effects of some metabolites of pyritinol (Encephabol) on ACH release from brain slices. Pharmacopsychiatry 21, Suppl 1:33–36PubMedCrossRefGoogle Scholar
  621. 12.
    Nachbar F, Korting HC, Vogl T (1993) Erythema multiforme-like eruptions in association with severe headache following pyritinol. Dermatol 187:42–46CrossRefGoogle Scholar
  622. 13.
    Pavlik A, Pilar J (1989) Protection of cell proteins against free-radical attack by noontropic drugs: scavenger effect of pyritinol confirmed by electron spin resonance spectroscopy. Neuropharmacol 28:557–561CrossRefGoogle Scholar
  623. 14.
    Toldedano A, Bentura ML (1994) Pyritinol facilitates the recovery of cortical cholinergic deficits caused by nucleus basalis lesions. J Neural Transm 7:195–209CrossRefGoogle Scholar
  624. 15.
    Tursky T (1988) Pyritinol inhibition of the GABA and benzdiazepine receptor. Physiol Behemoslov 37:417–426Google Scholar
  625. 16.
    Wild K, Simons P, Schoeppner H (1992) Effect of pyritinol on EEG and SSEP in comatose patients in the acute phase of intensive care therapy. Pharmacopsychiatry 25:157–165CrossRefGoogle Scholar
  626. 1.
    US Pat. 31010966, zit. nach CA (1962) 56:13022FGoogle Scholar
  627. 2.
    Datenblatt der Firma E. Merck, DarmstadtGoogle Scholar
  628. 1.
    Neumüller OA (1979) Römpps Chemie-Lexikon, Frankh’sche Verlagshandlung StuttgartGoogle Scholar
  629. 2.
    Sadtler-KatalogGoogle Scholar
  630. 3.
    Merck DatenblätterGoogle Scholar
  631. 4.
    Pachaly P (1995) DC-Atlas, Wiss. Verlagsges. StuttgartGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1999

Authors and Affiliations

  • Franz von Bruchhausen
    • 1
  • Siegfried Ebel
    • 2
  • Eberhard Hackenthal
    • 3
  • Ulrike Holzgrabe
    • 2
  • Margitta Albinus
    • 4
  • Gudrun Amschler
    • 5
  • Erwin von Angerer
    • 6
  • C. Arras-Reiter
    • 7
  • Andrea Bauer
    • 8
  • Pia Bauer
    • 9
  • Winfried Beil
    • 10
  • Thorsten Beyrich
    • 11
  • Katja Binder
    • 12
  • Roswitha Böhme
    • 13
  • Hans-Hubertus Borchert
    • 14
  • Franz Bossle
    • 15
  • Franz Bracher
    • 16
  • Helmut Bräunlich
    • 17
  • Ellen Bretschneider
    • 18
  • Regina Brigelius-Flohé
    • 19
  • Kerstin Brinkmann
    • 20
  • Axel Büge
    • 21
  • Wolfram Christ
    • 22
  • Monika Cimbollek
    • 23
  • Rolf Daniels
    • 24
  • Gerd Dannhardt
    • 25
  • Hans-Jürgen Duchstein
    • 26
  • Kurt Eger
    • 27
  • Petra Eichhorn
    • 28
  • Michael Engler
    • 29
  • Thomas Erker
    • 30
  • Peter Felfe
    • 31
  • Alfred Fenyves
    • 32
  • Reinhard Fescharek
    • 33
  • Carmen Frackenpohl
    • 34
  • August Wilhelm Frahm
    • 35
  • Margarete Frahm
  • Volker Franke
    • 36
  • Ulrich Franken
    • 37
  • Detlef Geffken
    • 38
  • Uli Geis
    • 39
  • Erika Glusa
    • 40
  • Berthold Göber
    • 41
  • Peter Ndive Gobina
    • 42
  • Werner Golder
    • 43
  • Margarete Goppelt-Strübe
    • 44
  • Katharina Götte
    • 45
  • Erkme Gottstein
    • 46
  • Michael Grosam
  • Markus von Gruchalla
    • 47
  • Michael Gütschow
    • 48
  • Annette Häfner
    • 49
  • Boris Haluszczynski
    • 50
  • Achim Harder
    • 51
  • Sabine Hartmann
    • 52
  • Susanne Hartmann
    • 53
  • Dieter Heber
    • 54
  • Gerhard Heinemeyer
    • 55
  • Eberhard Heller
    • 56
  • Dietrich von Herrath
    • 57
  • J. Hilfenhaus
  • Ute Hoffmann-Schollmayer
    • 58
  • Bernhard Hofmann
    • 59
  • Christian Holpert
    • 60
  • Ute Hübner-Steiner
    • 61
  • Elisabeth Inkmann
    • 62
  • Jens Jürgens
    • 63
  • Brigitte Kaiser
    • 64
  • Dieter-Abbo Kalbhen
    • 65
  • Hans Kemmler
    • 66
  • Werner Kiefer
    • 67
  • Christoph Klett
    • 68
  • Stephanie Klett
    • 69
  • Martin Klingmüller
    • 70
  • Hans-Peter Klöcking
    • 71
  • Gerd Kobal
    • 72
  • Axel Kramer
    • 73
  • Mareta Kreher
    • 74
  • M. Krüger
    • 75
  • Markus Kuhn
    • 76
  • Marion Sylvia Lehner
    • 77
  • Detlef Leopoldt
    • 78
  • Georg Liedtke
    • 79
  • Detlef Manns
    • 80
  • Wolfgang Matthiessen
    • 81
  • Andreas Maurer
    • 82
  • Wolfgang Meindl
    • 83
  • Klaus Menges
    • 84
  • Paul Messinger
    • 85
  • Frank Peter Meyer
    • 86
  • Wolfgang Meyerhof
    • 87
  • Manfred Moos
    • 88
  • Rudolf Morgenstern
    • 89
  • Klaus Müller
    • 90
  • Walter E. Müller
    • 91
  • Corina Nachtsheim
    • 92
  • Tilo Netzer
    • 93
  • Michael Neugebauer
    • 94
  • Werner Neupert
    • 95
  • Peter Nickel
    • 96
  • Peter Nuhn
    • 97
  • Bernd Nürnberg
    • 98
  • H. Oelschläger
    • 99
  • Joachim Oertel
    • 100
  • Michael Oettel
    • 101
  • Hartmut Oßwald
    • 102
  • Robert Ott
    • 103
  • Tilmann Ott
    • 104
  • Thomas Otzen
    • 105
  • Peter Pachaly
    • 106
  • Helmut Pelzer
    • 107
  • Karl-Uwe Petersen
    • 108
  • Rainer Pick
    • 109
  • Martina Pickert
    • 110
  • Andreas Pies
    • 111
  • Eberhard Reimann
    • 112
  • Joachim Richter
    • 113
  • Kai Riecke
    • 114
  • Suzanne Ritter
    • 115
  • Hans Rommelspacher
    • 116
  • Ulrich Rose
    • 117
  • Gernot Roth
    • 118
  • Gerhard Rücker
    • 119
  • Judith Schäfer
    • 120
  • Joachim G. Schantl
    • 121
  • Helmut Schlager
    • 122
  • Hildegard Schleinitz
    • 123
  • Max Schmauß
    • 124
  • Helmut Schmidhammer
    • 125
  • Gerhard Schmidt
    • 126
  • Timo Schmidt
    • 127
  • B. Schneeweiß
    • 128
  • Johannes Schräder
    • 129
  • Thomas Schulz
    • 130
  • Gert Schulze
    • 131
  • Peter Schwanz
    • 132
  • Johannes Schweiger
    • 133
  • Gisela Skopp
    • 134
  • Gisela Skorka
    • 135
  • Kai Smolinka
    • 136
  • Ulrich Speck
    • 137
  • Ralf Stahlmann
    • 138
  • Herbert Stein
    • 139
  • Karlheinz Stiefvater
    • 140
  • Karl-Heinz Surborg
    • 141
  • Ulf Sürig
    • 142
  • Hubert Szelényi
    • 143
  • Istvan Szelenyi
    • 144
  • Alfred Täufel
    • 145
  • Ruth Thieroff-Ekerdt
    • 146
  • Reinhard Troschütz
    • 147
  • Michael Verborg
    • 148
  • Eugen J. Verspohl
    • 149
  • Sabine Vogel
    • 150
  • Franz-Josef Volk
    • 151
  • Thomas Vorwerk
    • 152
  • Jürgen Wallmann
    • 153
  • Martin Wenzel
    • 154
  • Marion Weyandt-Spangenberg
    • 155
  • Sandra Wich
    • 156
  • Reinhold Wintersteiger
    • 157
  • Frauke Woltmann
    • 158
  • Beate Wüst
    • 159
  • G. Zilow
    • 160
  • A. Kluge
  1. 1.Institut für PharmakologieFreie Universität BerlinBerlinDeutschland
  2. 2.Institut für Pharmazie und LebensmittelchemieUniversität WürzburgWürzburgDeutschland
  3. 3.DossenheimDeutschland
  4. 4.Pharmakologisches InstitutEberhard-Karls-UniversitätTübingenDeutschland
  5. 5.Pharmazeutisches InstitutUniversität FreiburgFreiburgDeutschland
  6. 6.Institut für PharmazieUniversität RegensburgRegensburgDeutschland
  7. 7.Chiron-BehringMarburgDeutschland
  8. 8.Institut für Pharmazie Fachbereich Chemie und PharmazieJohannes Gutenberg-Universität MainzMainzDeutschland
  9. 9.WelzheimDeutschland
  10. 10.Allgemeine Pharmakologie — Abteilung IMedizinische Hochschule HannoverHannoverDeutschland
  11. 11.Fachbereich PharmazieErnst-Moritz-Arndt-UniversitätGreifswaldDeutschland
  12. 12.HammelburgDeutschland
  13. 13.Sankt AugustinDeutschland
  14. 14.Institut für PharmazieHumboldt-Universität zu BerlinBerlinDeutschland
  15. 15.SchweinfurtDeutschland
  16. 16.Institut für PharmazieMünchenDeutschland
  17. 17.HermstedtDeutschland
  18. 18.Zentrum für Vaskuläre Biologie und MedizinFriedrich-Schiller-Universität Jena, Institut für Experimentelle Angiologie und HämostaseologieErfurtDeutschland
  19. 19.AG Vitamine/AtheroskleroseDeutsches Institut für ErnährungsforschungBergholz-RehbrückeDeutschland
  20. 20.GerbrunnDeutschland
  21. 21.Institut für Pharmazeutische ChemieMartin-Luther-UniversitätHalleDeutschland
  22. 22.Bundesinstitut für Arzneimittel und MedizinprodukteBerlinDeutschland
  23. 23.MannheimDeutschland
  24. 24.Institut für PharmazieUniversität RegensburgRegensburgDeutschland
  25. 25.Institut für Pharmazie Fachbereich Chemie und PharmazieJohannes Gutenberg-UniversitätMainzDeutschland
  26. 26.Institut für Pharmazie Abteilung Pharmazeutische ChemieUniversität HamburgHamburgDeutschland
  27. 27.Institut für PharmazieUniversität LeipzigLeipzigDeutschland
  28. 28.SeeheimDeutschland
  29. 29.Pharmazeutisches InstitutUniversität BonnBonnDeutschland
  30. 30.Pharmaziezentrum der Universität WienWienDeutschland
  31. 31.RiemersortDeutschland
  32. 32.DietzenbachDeutschland
  33. 33.Sankyo Pharma GmbHMünchenDeutschland
  34. 34.Pharmazeutisches InstitutBonnDeutschland
  35. 35.Lehrstuhl für Pharmazeutische ChemieUniversität Freiburg, Pharmazeutisches InstitutFreiburgDeutschland
  36. 36.Behringwerke AGMarburgDeutschland
  37. 37.Balneopharm Cordes & Co.GarbsenDeutschland
  38. 38.Abteilung für Pharmazeutische ChemieInstitut für PharmazieHamburgDeutschland
  39. 39.WürzburgDeutschland
  40. 40.Institut für Experimentelle Angiologie und Hämostaseologie Zentrum für Vaskuläre Biologie und MedizinKlinikum der Friedrich-Schiller-Universität JenaErfurtDeutschland
  41. 41.Institut für PharmazieHumboldt-Universität zu BerlinBerlinDeutschland
  42. 42.Pharmazeutisches InstitutBonnDeutschland
  43. 43.Fachbereich Humanmedizin, Radiologische Klinik u. Poliklinik, Abt. f. Radiologische Diagnostik und NuklearmedizinUniversitätsklinikum Benjamin FranklinBerlinDeutschland
  44. 44.Nephrologisches ForschungslaborMed. Klinik IV mit Poliklinik, Friedrich-Alexander-UniversitätErlangenDeutschland
  45. 45.Institut für Pharmazie und LebensmittelchemieUniversität WürzburgWürzburgDeutschland
  46. 46.Apotheke KKH Bad SegebergBad SegebergDeutschland
  47. 47.Fachbereich Chemie und PharmazieJohannes Gutenberg-Universität, Institut für PharmazieMainzDeutschland
  48. 48.Institut für PharmazieUniversität LeipzigLeipzigDeutschland
  49. 49.Pharmazeutisches InstitutAlbert-Ludwigs-UniversitätFreiburgDeutschland
  50. 50.WürzburgDeutschland
  51. 51.Geschäftsbereich TiergesundheitBayer AG, Institut für ParasitologieLeverkusenDeutschland
  52. 52.Seeheim-JugenheimDeutschland
  53. 53.Pharmazeutisches InstitutUniversität FreiburgFreiburgDeutschland
  54. 54.Pharmazeutisches InstitutUniversität KielKielDeutschland
  55. 55.Max-von-Pettenkofer-Institut, Bundesinstiut für gesundheitlichenVerbraucherschutz und VeterinärmedizinBerlinDeutschland
  56. 56.RandersackerDeutschland
  57. 57.Medizinische Abteilung IISt. Joseph KrankenhausBerlinDeutschland
  58. 58.GerbrunnDeutschland
  59. 59.Abteilung für NeuroendokrinologieMPI für experimentelle MedizinGöttingenDeutschland
  60. 60.MömbrisDeutschland
  61. 61.Schering AG, Forschung DiagnostikaGeschäftsbereich PharmaBerlinDeutschland
  62. 62.Pharmazeutisches InstitutBonnDeutschland
  63. 63.Rottendorf Pharma GmbHEnnigerlohDeutschland
  64. 64.Zentrum für vaskuläre Biologie und Medizin ErfurtFriedrich-Schiller-Universität JenaErfurtDeutschland
  65. 65.Institut für Pharmakologie und ToxikologieUniversität BonnBonnDeutschland
  66. 66.Bundesinstitut für Arzneimittel und MedizinprodukteBerlinDeutschland
  67. 67.Fachbereich Chemie und PharmazieJohannes Gutenberg-Universität Mainz, Institut für PharmazieMainzDeutschland
  68. 68.Department of Pharmacology 0636University of California, San DiegoLa JollaUSA
  69. 69.HöchbergDeutschland
  70. 70.Wardenburg-WesterburgDeutschland
  71. 71.Institut für Pharmakologie und Toxikologie/Bereich Erfurt, Pharmazeutische Pharmakologie und ToxikologieKlinikum der Friedrich-Schiller-Universität JenaErfurtDeutschland
  72. 72.Institut für Experimentelle und Klinische Pharmakologie und ToxikologieUniversität Erlangen-NürnbergErlangenDeutschland
  73. 73.Medizinische Fakultät/Institut für Hygiene und UmweltmedizinErnst-Moritz-Arndt-UniversitätGreifswaldDeutschland
  74. 74.Fachbereich Chemie und PharmazieJohannes Gutenberg-Universität Mainz, Institut für PharmazieMainzDeutschland
  75. 75.Institut für Mikrobielle TierseuchenLeipzigDeutschland
  76. 76.BiberachDeutschland
  77. 77.WindischeschenbachDeutschland
  78. 78.OtterndorfDeutschland
  79. 79.Pharmazeutisches InstitutBonnDeutschland
  80. 80.Pharmazeutisches InstitutUniversität BonnBonnDeutschland
  81. 81.Fachkrankenhaus CoswigZentrum für Pneumologie und ToraxchirurgieCoswig/DresdenDeutschland
  82. 82.Pharmazeutisches InstitutAlbert-Ludwigs-UniversitätFreiburgDeutschland
  83. 83.Institut für PharmazieUniversität RegensburgRegensburgDeutschland
  84. 84.Bundesinstitut für Arzneimittel und MedizinprodukteBerlinDeutschland
  85. 85.Abt. Pharmazeutische ChemieUniversität Hamburg Institut für PharmazieHamburgDeutschland
  86. 86.Medizinische Fakultät, Institut für Klinische PharmakologieOtto-von-Guericke-UniversitätMagdeburgDeutschland
  87. 87.Deutsches Institut für Ernährungsforschung, Potsdam-RehbrückePotsdam-RehbrückeDeutschland
  88. 88.Abteilungsleiter VeterinärmedizinPaul-Ehrlich-InstitutLangenDeutschland
  89. 89.Medizinische Fakultät der Humboldt-Universität zu Berlin, Institut für Pharmakologie und ToxikologieUniversitätsklinikum CharitéBerlinDeutschland
  90. 90.Institut für Pharmazeutische ChemieUniversität MünsterMünsterDeutschland
  91. 91.Pharmakologisches Institut für NaturwissenschaftFrankfurtDeutschland
  92. 92.BonnDeutschland
  93. 93.Frankfurt/M.Deutschland
  94. 94.Pharmazeutisches InstitutUniversität BonnBonnDeutschland
  95. 95.Forschungslabors des Lehrstuhls für Innere Medizin IVMedizinische Klinik IV mit Poliklinik, Friedrich-Alexander-Universität Erlangen-NürnbergNürnbergDeutschland
  96. 96.Pharmazeutisches InstitutUniversität BonnBonnDeutschland
  97. 97.Fachbereich PharmazieMartin-Luther-Universität, Institut für Pharmazeutische ChemieHalle/S.Deutschland
  98. 98.Institut für PharmakologieFreie Universität BerlinBerlinDeutschland
  99. 99.Institut für PharmazieFriedrich-Schiller-Universität JenaJenaDeutschland
  100. 100.Hämatologisch-onkologische AbteilungCharité, Campus Virchow-Klinikum, Humboldt-UniversitätBerlinDeutschland
  101. 101.Jenapharm GmbH & Co. KGJenaDeutschland
  102. 102.Pharmakologisches InstitutEberhard-Karls-UniversitätTübingenDeutschland
  103. 103.Institut für Pharmazeutische ChemieUniversität GrazGrazAustria
  104. 104.Bundesinstitut für Arzneimittel und MedizinprodukteBerlinDeutschland
  105. 105.SchleswigDeutschland
  106. 106.Pharmazeutisches Institut PoppelsdorfBonnDeutschland
  107. 107.UlmDeutschland
  108. 108.AachenDeutschland
  109. 109.Pharmazeutisches Institut PoppelsdorfRheinische Friedrich-Wilhelms-Universität BonnBonnDeutschland
  110. 110.Pharmazeutisches InstitutUniversität FreiburgFreiburgDeutschland
  111. 111.Fachbereich Chemie und PharmazieJohannes Gutenberg-Universität Mainz, Institut für PharmazieMainzDeutschland
  112. 112.Institut für Pharmazie und LebensmittelchemieUniversität MünchenMünchenDeutschland
  113. 113.BerlinDeutschland
  114. 114.Abteilung ToxikologieUniversitätsklinikum Benjamin Franklin Institut für Klinische Pharmakologie und ToxikologieBerlinDeutschland
  115. 115.KönigsbrunnDeutschland
  116. 116.Institut für NeuropsychopharmakologieFreie Universität BerlinBerlinDeutschland
  117. 117.Council of EuropeEuropean Pharmacopoeia CommissionStrasbourgFrance
  118. 118.HaibachDeutschland
  119. 119.Pharmazeutisches InstitutUniversität BonnBonnDeutschland
  120. 120.Deutsches Institut für Ernährungsforschung, Potsdam-RehbrückeUniversität PotsdamBergholz-RehbrückeDeutschland
  121. 121.Institut für Organische ChemieUniversität InnsbruckInnsbruckAustria
  122. 122.WürzburgDeutschland
  123. 123.Rhône-Poulenc Rorer GmbHKölnDeutschland
  124. 124.Klinik für Psychiatrie und PsychotherapieAugsburgDeutschland
  125. 125.Institut für Pharmazeutische ChemieInnsbruckAustria
  126. 126.Zentrum Pharmakologie und ToxikologieUniversität GöttingenGöttingenDeutschland
  127. 127.GrafenrheinfeldDeutschland
  128. 128.BerlinDeutschland
  129. 129.Zentrales Institut des Sanitätsdienstes der BundeswehrKronshagenDeutschland
  130. 130.GöttingenDeutschland
  131. 131.Institut für NeuropsychopharmakologieBerlinDeutschland
  132. 132.Pharmazeutisches InstitutUniversität FreiburgFreiburgDeutschland
  133. 133.Dom ApothekeFreisingDeutschland
  134. 134.Institut für RechtsmedizinUniversität HeidelbergHeidelbergDeutschland
  135. 135.Institut für Pharmakologie und ToxikologieMed. Fakultät der HU zu BerlinBerlinDeutschland
  136. 136.Institut für PharmazieHumboldt-Universität BerlinBerlinDeutschland
  137. 137.Schering AG, Forschung DiagnostikaGeschäftsbereich PharmaBerlinDeutschland
  138. 138.Institut für Klinische Pharmakologie und Toxikologie Abteilung ToxikologieUniversitätsklinikum Benjamin FranklinBerlinDeutschland
  139. 139.Bundesinstitut für Arzneimittel und MedizinprodukteBerlinDeutschland
  140. 140.Apotheke des Klinikums der Stadt MannheimMannheimDeutschland
  141. 141.St. AugustinDeutschland
  142. 142.Solvay PharmaWerk NeustadtNeustadtDeutschland
  143. 143.Innere Medizin: Schwerpunkt Hämatologie u. OnkologieUni-Klinikum Benjamin FranklinBerlinDeutschland
  144. 144.Arzneimittelwerk Dresden GmbHPharmakologische Forschung, FP-2RadebeulDeutschland
  145. 145.Abteilung Präventiv-Medizin, LebensmittelforschungDt. Institut für ErnährungsforschungBergholz-RehbrückeDeutschland
  146. 146.Schering AGZentrum für DermatologieBerlinDeutschland
  147. 147.Institut für Pharmazie und LebensmittelchemieErlangenDeutschland
  148. 148.Arzneimittelüberwachungsstelle SHKielDeutschland
  149. 149.Pharmakologie für NaturwissenschaftlerWestfälische Wilhelms-Universität, Institut für Pharmazeutische ChemieMünsterDeutschland
  150. 150.NailaDeutschland
  151. 151.Pharmazeutisches InstitutAlbert-Ludwigs-UniversitätFreiburgDeutschland
  152. 152.Institut für PharmazieHumboldt-Universität zu BerlinBerlinDeutschland
  153. 153.BerlinDeutschland
  154. 154.WEH: Institut für PharmazieBerlinDeutschland
  155. 155.OffenburgDeutschland
  156. 156.MarktrodachDeutschland
  157. 157.Institut für Pharmazeutische ChemieKarl-Franzens-UniversitätGrazAustria
  158. 158.MannheimDeutschland
  159. 159.Pharmazeutisches InstitutBonnDeutschland
  160. 160.Institut für ImmunologieHeidelbergDeutschland

Personalised recommendations